

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 581 500 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
09.09.1998 Bulletin 1998/37

(51) Int Cl.⁶: **C07D 477/00, C07D 401/12,
C07F 9/568, C07D 401/14,
C07D 403/12, C07D 403/14,
A61K 31/40**

(21) Application number: **93305607.9**

(22) Date of filing: **16.07.1993**

(54) Antibiotic carbapenem compounds

Antibiotische Carbapenemverbindungen

Dérivés de carbapénème antibiotiques

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE**

(30) Priority: **21.07.1992 EP 92402105**

(43) Date of publication of application:
02.02.1994 Bulletin 1994/05

(73) Proprietors:
• **ZENECA LIMITED**
London W1Y 6LN (GB)
• **ZENECA Pharma S.A.**
95022 Cergy Pontoise Cédex (FR)

(72) Inventors:
• **Jung, Frederic Henri**
F-51064 Reims Cedex (FR)

• **Arnould, Jean-Claude**
F-51064 Reims Cedex (FR)

(74) Representative:
Denerley, Paul Millington, Dr. et al
Intellectual Property Department
ZENECA Pharmaceuticals
Mereside
Alderley Park
Macclesfield, Cheshire SK10 4TG (GB)

(56) References cited:
EP-A- 0 126 587 **EP-A- 0 443 883**
WO-A-92/17481

EP 0 581 500 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description


The present invention relates to carbapenems and in particular to such compounds containing a carboxy substituted bicyclic nitrogen containing ring system. This invention further relates to processes for their preparation, to intermediates in their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them. The compounds of this invention are antibiotics and can be used in the treatment of any disease that is conventionally treated with antibiotics for example in the treatment of bacterial infection in mammals including humans.

Carbapenems were first isolated from fermentation media in 1974 and were found to have broad spectrum antibacterial activity. Since this discovery substantial investigations have been made into new carbapenem derivatives and many hundreds of patents and scientific papers have been published.


The first, and so far the only, carbapenem to be commercially marketed is imipenem (N-formimidoyl thienamycin). This compound has a broad spectrum of antibacterial activity.

The present invention provides compounds with a broad spectrum of antibacterial activity including both Gram positive and negative, aerobic and anaerobic bacteria. They exhibit good stability to beta-lactamases. In addition representative compounds of this invention exhibit favourable pharmacokinetics.

The carbapenem derivatives referred to herein are named in accordance with the generally accepted semi-systematic nomenclature:



Accordingly the present invention provides a compound of the formula (I)




wherein:

R¹ is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl;

R² is hydrogen or C₁₋₄alkyl;

R³ is hydrogen or C₁₋₄alkyl;

P is of the formula:



and one or two of A,B,C,D,E,F,G and H, are nitrogen and the remainder are CH; and P¹ is bonded to the nitrogen of the linking carbamoyl group by a carbon atom, in either ring, is substituted by the carboxy group on a carbon atom, in either ring, and is optionally further substituted, on a carbon atom, in either ring, by up to three substituents

selected from halo, cyano, C₁₋₄alkyl, nitro, hydroxy, carboxy, C₁₋₄alkoxy, trifluoromethyl, C₁₋₄alkoxycarbonyl, amino, C₁₋₄alkylamino, di-C₁₋₄alkylamino, C₁₋₄alkylS(O)_n- (wherein n is 0-2), C₁₋₄alkanoylamino, C₁₋₄alkanoyl(N-C₁₋₄alkyl)amino, carbamoyl, C₂₋₆alkenyloxy, C₁₋₄alkylcarbamoyl and di-C₁₋₄alkylcarbamoyl; or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

The term alkyl includes all straight and branched chain structures, for example, C₁₋₄alkyl includes n-butyl and 2-methylpropyl.

Preferably R¹ is 1-hydroxyethyl.

R² is hydrogen or C₁₋₄alkyl for example methyl, ethyl, n-propyl, 1-methylethyl and n-butyl.

Preferably R² is hydrogen or methyl and in particular R² is methyl.

Particular bicyclic ring systems for P are quinoline, isoquinoline, phthalazine, quinoxaline, quinazoline, cinnoline, 1,8-naphthyridine, 1,7-naphthyridine, 1,6-naphthyridine, 1,5-naphthyridine, 2,7-naphthyridine and 2,6-naphthyridine.

Preferably P¹ is quinoline, isoquinoline, quinoxaline or quinazoline. In another aspect P¹ is quinoline, quinoxaline or quinazoline. Most preferably P¹ is quinoline.

R³ is hydrogen or C₁₋₄alkyl for example methyl, ethyl, n-propyl, 1-methylethyl and n-butyl.

Preferably R³ is hydrogen or methyl.


Most preferably R³ is hydrogen.

Suitable substituents for the bicyclic ring system include, for example:-


for halo	fluoro, chloro, bromo and iodo;
for C ₁₋₄ alkyl	methyl, ethyl, propyl, 1-methylethyl, butyl and 2-methylpropyl;
for C ₁₋₄ alkoxy	methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy and 2-methylpropoxy;
for C ₁₋₄ alkylcarbamoyl	methylcarbamoyl, ethylcarbamoyl and propylcarbamoyl;
for di-C ₁₋₄ alkylcarbamoyl	dimethylcarbamoyl and diethylcarbamoyl;
for C ₁₋₄ alkylamino	methylamino, ethylamino and propylamino;
for di-C ₁₋₄ alkylamino	dimethylamino, diethylamino and methylethylamino;
for C ₁₋₄ alkylS(O) _n -	methylthio, methylsulfinyl and methylsulfonyl;
for C ₁₋₄ alkanoylamino	acetamido and propionamido;
for C ₁₋₄ alkanoyl(N-C ₁₋₄ alkyl)amino	<u>N</u> -methylacetamido and <u>N</u> -ethylacetamido;
for C ₂₋₆ alkenyloxy	allyloxy and vinyloxy.

Preferably when P¹ is optionally substituted, the optional substituents are selected from halo, cyano, C₁₋₄alkyl, nitro, carboxy, hydroxy, C₁₋₄alkoxy, carbamoyl, amino, trifluoromethyl and allyloxy.

The present invention covers all epimeric, diastereoisomeric and tautomeric forms of the compounds of the formula (I) wherein the absolute stereochemistry at the 5-position is as illustrated in formula (I). When a bond is represented as a wedge, this indicates that in three dimensions the bond would be coming forward out of the paper and when a bond is represented as hatched, this indicates that in three dimensions the bond would be going back into the paper. The compounds of the formula (I) have a number of other centres of optical activity, namely: within the group R¹ (when R¹ is 1-hydroxyethyl or 1-fluoroethyl); at the 6-position; at the 1-position (when R² is C₁₋₄alkyl); and at the 2' and 4' positions in the pyrrolidine ring:



Preferred compounds are those in which the beta-lactam protons are in trans configuration with respect to one another. When R¹ is 1-hydroxyethyl or 1-fluoroethyl it is preferred that the 8-substituent has the R-configuration. Thus a preferred class of compounds is that of the formula (III):




and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof, wherein P¹, R², R³ and optional substituents on P¹ are as hereinbefore defined.

15 When R² is C₁₋₄alkyl for example methyl it is preferred that the compound is in the form of the 1R configuration.

Preferred compounds are those in which the pyrrholidine ring has the following absolute stereochemistry at the 2'- and 4'-positions:



A suitable class of compounds of the present invention is that of the formula (IV):



40 and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof; wherein P¹, R³ and optional substituents on P¹ are as defined hereinbefore in formula (I).

In another aspect a suitable class of compounds are the compounds of the formula (IV) wherein R³ is hydrogen, methyl or ethyl; and P¹ and optional substituents on P¹ are as defined hereinabove in formula (I).

45 In yet another aspect a suitable class of compounds is that of the compounds of the formula (IV) wherein P¹ is optionally further substituted by one or two substituents selected from methyl, ethyl, hydroxy, carboxy, cyano, fluoro, chloro, bromo, carbamoyl, nitro, methoxy, ethoxy, propoxy and allyloxy; and P¹ and R³ are as defined hereinbefore in formula (I).

50 A particular class of compounds of the present invention is that of the formula (IV) wherein:

R³ is hydrogen or methyl;

P¹ is as hereinabove defined in formula (I);

and P¹ is optionally further substituted by one or two substituents selected from methyl, ethyl, hydroxy, carboxy, cyano, chloro, bromo, nitro, methoxy, ethoxy and allyloxy.

55 A preferred class of compounds of the present invention is that of the formula (IV) wherein:

R³ is hydrogen;

P¹ is as hereinabove defined in formula (I);

and P¹ is optionally further substituted by one or two substituents selected from methyl, hydroxy, chloro, carboxy and allyloxy.

A more preferred class of compounds of the present invention is that of the formula (IV) wherein:

R³ is hydrogen;

P¹ is as hereinabove defined in formula (I);

and P¹ is not further substituted.

Particular compounds of the present invention are, for example, the following compounds of the formula (IV):

(1R,5S,6S,8R,2'S,4'S)-2-(2-(8-carboxyquinol-6-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid; and

(1R,5S,6S,8R,2'S,4'S)-2-(2-(6-carboxyquinol-8-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;

(1R,5S,6S,8R,2'S,4'S)-2-(2-(7-carboxyquinol-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;

(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyquinol-2-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;

(1R,5S,6S,8R,2'S,4'S)-2-(2-(2-carboxyquinol-4-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;

(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-allyloxyquinol-2-ylcarbamoyl)-pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;

(1R,5S,6S,8R,2'S,4'S)-2-(2-(2-carboxyquinol-6-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;

(1R,5S,6S,8R,2'S,4'S)-2-(2-(4-carboxyquinol-8-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;

(1R,5S,6S,8R,2'S,4'S)-2-(2-(4-carboxyquinol-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;

(1R,5S,6S,8R,2'S,4'S)-2-(2-(2-carboxyquinol-8-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;

(1R,5S,6S,8R,2'S,4'S)-2-(2-(2-carboxyquinol-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;

(1R,5S,6S,8R,2'S,4'S)-2-(2-(4-carboxyquinol-2-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;

(1R,5S,6S,8R,2'S,4'S)-2-(2-(7-carboxy-2,3-dimethylquinoxalin-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;

(1R,5S,6S,8R,2'S,4'S)-2-(2-(4-carboxyquinazolin-2-ylcarbamoyl)-pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;

(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyisoquinol-5-ylcarbamoyl)-pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;

and pharmaceutically acceptable salts and *in vivo* hydrolysable esters thereof.

Suitable pharmaceutically acceptable salts include acid addition salts such as hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulfuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, *N*-methylpiperidine, *N*-ethylpiperidine, procaine, dibenzylamine, *N,N*-dibenzylethylamine or aminoacids, for example, lysine.

For the avoidance of doubt there may be one, two, three or four salt-forming cations depending on the number of carboxylic acid functions and valency of said cations.

Preferred pharmaceutically acceptable salts are sodium and potassium salts. However, to facilitate isolation of the salt during preparation, salts which are less soluble in the chosen solvent may be preferred, whether pharmaceutically acceptable or not.

In vivo hydrolysable esters are those pharmaceutically acceptable esters that hydrolyse in the human body to produce the parent hydroxy or carboxy compound. Such esters can be identified by administering, eg. intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluids. Suitable *in vivo* hydrolysable esters for hydroxy include acetoxo, propionyloxy, pivaloyloxy, C₁₋₄alkoxycarbonyloxy for example ethox-

ycarbonyloxy, phenylacetoxymethyl and phthalidyl. Suitable in vivo hydrolysable esters for carboxy include C₁₋₆alkoxymethyl esters for example methoxymethyl; C₁₋₆alkanoyloxymethyl esters for example pivaloyloxymethyl; C₃₋₈ cycloalkoxycarbonyloxyC₁₋₆alkyl, for example 1-cyclohexyloxycarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; phthalidyl esters and C₁₋₆alkoxycarbonyloxyethyl esters for example 1-ethoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

In order to use a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for the therapeutic treatment of mammals including humans, in particular in treating infection, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof and a pharmaceutically acceptable carrier.

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, rectal or parenteral administration. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions or suspensions, emulsions, dispersible powders, suppositories and sterile injectable aqueous or oily solutions or suspensions.

The compounds of the present invention may be formulated as dry powder filled vials, which may contain the compound of the present invention alone or as a dry blended mixture. For example an acidic compound of the present invention may be dry blended with an alkali metal carbonate or bicarbonate. Freeze dried formulations of compounds of the present invention, alone or as a mixture with standard excipients, are possible. Standard excipients include structure formers, cryoprotectants and pH modifiers, such as, mannitol, sorbitol, lactose, glucose, sodium chloride, dextran, sucrose, maltose, gelatin, bovine serum albumin (BSA), glycine, mannose, ribose, polyvinylpyrrolidone (PVP), cellulose derivatives, glutamine, inositol, potassium glutamate, erythritol, serine and other amino acids and buffer agents e.g. disodium hydrogen phosphate and potassium citrate.

In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain, or be co-administered with, one or more known drugs selected from other clinically useful antibacterial agents (for example other beta-lactams or aminoglycosides), inhibitors of beta-lactamase (for example clavulanic acid), renal tubular blocking agents (e.g. probenecid) and inhibitors of metabolising enzymes (for example inhibitors of dehydropeptidases, for example Z-2-acylamino-3-substituted propenoates such as cilastatin) and N-acylated amino acids such as betamipron (also see EP-A-178911).

A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 100mg and 1g of the compound of this invention.

A preferred pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection, for example a sterile injectable composition containing between 1 and 50% w/w of the compound of this invention.

Specific examples of compositions, which are constituted as a 1% solution in water, freeze dried and may be made up by adding 0.9% aqueous sodium chloride solution to give the required concentration, preferably 1mg-10mg/ml, as follows:

Composition 1

Compound of Example 1	50mg
-----------------------	------

Composition 2


Compound of Example 1	50mg
Glycine	31mg

Further specific examples of compositions are as above, but where the compound of example 1 is replaced by any one of examples 2 to 15.

The pharmaceutical compositions of the invention will normally be administered to man in order to combat infections caused by bacteria, in the same general manner as that employed for imipenem due allowance being made in terms of dose levels for the pharmacokinetics of the compound of the present invention relative to the clinical use of imipenem. Thus each patient will receive a daily intravenous, subcutaneous or intramuscular dose of 0.05 to 5g, and preferably 0.1 to 2.5g, of the compound of this invention, the composition being administered 1 to 4 times per day, preferably 1 or 2 times a day. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose. Thus a suitable daily oral

dose is 0.05 to 5g. of the compound of this invention, the composition being administered 1 to 4 times per day.

In a further aspect the present invention provides a process for preparing the compounds of the formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof which process comprises deprotecting a compound of the formula (V) wherein P is optionally further substituted as in formula (I):



wherein P¹ is as hereinbefore defined; R² is as hereinbefore defined; R¹⁰ is a group R³ or an amino protecting group; R¹³ is a group R¹, protected hydroxymethyl or 1-(protected hydroxy)ethyl; R¹¹ is hydrogen or a carboxy protecting group; R¹² is hydrogen or an amino protecting group, R¹⁸ is carboxy or a protected carboxy group and wherein any optional substituent on P¹ is optionally protected; and wherein at least one protecting group is present; and thereafter if necessary;

- (i) forming a pharmaceutically acceptable salt,
- (ii) esterifying to form an *in vivo* hydrolysable ester.

Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question, and may be introduced by conventional methods.

Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.

The compounds of the formula (V) are novel and form another aspect of the invention.

Specific examples of protecting groups are given below for the sake of convenience, in which "lower" signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods for the removal of protecting groups are given below these are similarly not exhaustive. The use of protecting groups and methods of deprotection not specifically mentioned is of course within the scope of the invention.

A carboxy protecting group may be the residue of an ester-forming aliphatic or araliphatic alcohol or of an ester-forming silanol (the said alcohol or silanol preferably containing 1-20 carbon atoms).

Examples of carboxy protecting groups include straight or branched chain (1-12C)alkyl groups (eg isopropyl, *t*-butyl); lower alkoxy lower alkyl groups (eg methoxymethyl, ethoxymethyl, isobutoxymethyl); lower aliphatic acyloxy lower alkyl groups, (eg acetoxymethyl, propionyloxymethyl, butyryloxymethyl, pivaloyloxymethyl); lower alkoxy carbonyloxy lower alkyl groups (eg 1-methoxycarbonyloxyethyl, 1-ethoxycarbonyloxyethyl); aryl lower alkyl groups (eg *p*-methoxybenzyl, *o*-nitrobenzyl, *p*-nitrobenzyl, benzhydryl and phthalidyl); tri(lower alkyl)silyl groups (eg trimethylsilyl and *t*-butyldimethylsilyl); tri(lower alkyl)silyl lower alkyl groups (eg trimethylsilylethyl); diaryl(lower alkyl)silyl groups (eg *t*-butyldiphenylsilyl); and (2-6C)alkenyl groups (eg allyl and vinyl ethyl).

Methods particularly appropriate for the removal of carboxyl protecting groups include for example acid-, base-, metal- or enzymically-catalysed hydrolysis, for groups such as *p*-nitrobenzyloxycarbonyl, hydrogenation and for groups such as *o*-nitrobenzyloxycarbonyl, photolytically.

Examples of hydroxyl protecting groups include lower alkenyl groups (eg allyl); lower alkanoyl groups (eg acetyl); lower alkoxy carbonyl groups (eg *t*-butoxycarbonyl); lower alkenyloxycarbonyl groups (eg allyloxycarbonyl); aryl lower alkoxy carbonyl groups (eg benzoyloxycarbonyl, *p*-methoxybenzyloxycarbonyl, *o*-nitrobenzyloxycarbonyl, *p*-nitrobenzyloxycarbonyl); tri lower alkylsilyl (eg trimethylsilyl, *t*-butyldimethylsilyl); diaryl(lower alkyl)silyl groups (eg *t*-butyldiphenylsilyl) and aryl lower alkyl (eg benzyl) groups.


Examples of amino protecting groups include formyl, aralkyl groups (eg benzyl and substituted benzyl, eg *p*-methoxybenzyl, nitrobenzyl and 2,4-dimethoxybenzyl, and triphenylmethyl); di-*p*-anisylmethyl and furylmethyl groups; lower

alkoxycarbonyl (eg *t*-butoxycarbonyl); lower alkenyloxycarbonyl (eg allyloxycarbonyl); aryl lower alkoxycarbonyl groups (eg benzyloxycarbonyl, *p*-methoxybenzyloxycarbonyl, *o*-nitrobenzyloxycarbonyl, *p*-nitrobenzyloxycarbonyl); trialkylsilyl (eg trimethylsilyl and *t*-butyldimethylsilyl); diaryl(lower alkyl)silyl group (eg *t*-butyldiphenylsilyl); alkylidene (eg methy-
 5 lidene); benzylidene and substituted benzylidene groups.

Methods appropriate for removal of hydroxy and amino protecting groups include, for example, acid-, base-, metal-
 or enzymically-catalysed hydrolysis, for groups such as *p*-nitrobenzyloxycarbonyl, hydrogenation and for groups such
 as *o*-nitrobenzyloxycarbonyl, photolytically.


In another aspect of the present invention the compounds of the formulae (I) and (V) may be prepared by

a) reacting compounds of the formulae (VI) and (VII):



wherein P¹, R², R¹⁰, R¹¹, R¹², R¹³ and R¹⁸ are as hereinbefore defined, P¹ is optionally substituted hereinbefore
 defined and L is a leaving group, or

b) cyclising a compound of the formula (VIII):



wherein P¹, R², R¹⁰, R¹¹, R¹², R¹³ and R¹⁸ are as hereinbefore defined, P¹ is optionally substituted as hereinbefore
 defined and R¹⁴, R¹⁵ and R¹⁶ are independently selected from C₁₋₆alkoxy, aryloxy, di-C₁₋₆alkylamino and diarylami-
 no or any two of R¹⁴-R¹⁶ represent *o*-phenylenedioxy or one of R¹⁴-R¹⁶ is C₁₋₄alkyl, allyl, benzyl or phenyl and
 the other two values are independently selected from C₁₋₄alkyl, trifluoromethyl or phenyl, wherein any phenyl group
 is optionally substituted with C₁₋₃alkyl or C₁₋₃alkoxy; and wherein any functional group is optionally protected and
 thereafter if necessary:

- (i) removing any protecting groups;
- (ii) forming a pharmaceutically acceptable salt;
- (iii) esterifying to form an *in vivo* hydrolysable ester.


Suitably in the compound of the formula (VI), L is the reactive ester of a hydroxy group such as a sulphonate (for
 example C₁₋₆alkanesulphonyloxy, trifluoromethanesulphonyloxy, benzenesulphonyloxy, toluenesulphonyloxy), a phos-
 phoric ester (for example a diarylphosphoric ester such as diphenylphosphoric ester) or L is a halide (for example
 chloride). In an alternative L is a sulfoxide for example -SOCH=CH-NHCOCH₃ which may be readily displaced.
 Preferably L is diphenylphosphoric ester (-OP(O)(OPh)₂).

Compounds of the formula (VI) and their preparation are well known in the carbapenem literature, for example see
 EP-A-126587, EP-A-160391, EP-A-243686 and EP-A-343499.

The reaction between the compounds of the formulae (VI) and (VII) is typically performed in the presence of a
 base such as an organic amine for example di-isopropylethylamine or an inorganic base for example an alkali metal
 carbonate such as potassium carbonate. The reaction is conveniently performed at a temperature between -25°C and
 ambient. The reaction is generally performed in an organic solvent such as acetonitrile or dimethylformamide. The
 reaction is generally performed in a manner similar to that described in the literature for similar reactions.

The compounds of the formula (VII) are novel and form another aspect of the present invention.


The compounds of the formula (VII) may be prepared by the deprotection of a compound of the formula (IX):



wherein P¹, R¹⁰, R¹² and R¹⁸ are as hereinbefore defined, P¹ is optionally substituted as hereinbefore defined and R¹⁷ is a protecting group, for example C₁₋₆alkanoyl or C₁₋₆alkoxycarbonyl. Preferred values for R¹⁷ are acetyl and *t*-butoxycarbonyl. The compounds of the formula (IX) can be converted to the compounds of the formula (VII) by standard methods of deprotection, for example acetyl groups can be removed by basic hydrolysis in aqueous alkanol, alkanol for example with methylamine in ethanol.

The compounds of the formula (IX) are novel and form another aspect of the present invention.

The compounds of the formula (IX) may be prepared by the reaction of an activated derivative of a compound of the formula (X), which may be formed *in situ*, with a compound of the formula (XI):




wherein P¹, R¹⁰, R¹², R¹⁷ and R¹⁸ are as hereinbefore defined and P¹ is optionally substituted as hereinbefore defined. Activated derivatives of the compound of the formula (X) include acid halides, anhydrides and 'activated' esters such as 1H-benzol-1,2,3-triazol-1-yl, pentafluorophenyl and 2,4,5-trichlorophenyl esters or the benzimidazol-2-yl ester of the thiocarboxylic acid corresponding to (X). The reaction of the compounds of the formulae (X) and (XI) is performed under standard methods, for example in the presence of sulphonyl chloride at ambient temperature.

The compounds of the formulae (X) and (XI) are prepared by standard methods known to the skilled chemist such as the methods of the Examples hereinafter, the methods described in EP-A-126587 or by methods analogous or similar thereto. For example, bicyclic rings of the formula P¹ substituted with a methyl group on a ring carbon atom are converted to compounds of the formula (XI) by oxidating the methyl group to a carboxy group, nitrating the ring to introduce a nitro group and reducing the nitro group to an amino group. The oxidation, nitration and reduction steps involve standard methods known in the art.

Suitably, in the compounds of the formula (VIII), R¹⁴, R¹⁵ and R¹⁶ are independently selected from C₁₋₆ alkoxy such as methoxy, ethoxy, isopropoxy, n-propoxy or n-butoxy; aryloxy such as optionally phenoxy; di-C₁₋₆alkylamino such as dimethylamino or diethylamino; diarylamino such as diphenylamino or any two of R¹⁴-R¹⁶ represent *o*-phenylenedioxy. Preferably each of R¹⁴-R¹⁶ have the same value and are C₁₋₆alkoxy for example methoxy, ethoxy, isopropoxy or *n*-butoxy or are phenoxy.

The compounds of the formula (VIII) are cyclized under conventional conditions known in the art to form compounds of the formula (V). Typical conditions are heating in a substantially inert organic solvent such as toluene, xylene or ethyl acetate at temperatures in the region 60-150°C. Typically the reaction is performed in an atmosphere of nitrogen and is carried out in the presence of a radical scavenger for example hydroquinone.


The compounds of the formula (VIII) may be formed and cyclized *in situ*. The compounds of the formula (VIII) may conveniently be prepared by reacting compounds of the formulae (XII) and (XIII):



15 wherein P^1 , R^2 , R^{10} , R^{11} - R^{16} , and R^{18} are as hereinbefore defined and P^1 is optionally substituted as hereinbefore defined. Suitably the compound of the formula (XIII) is a phosphite or is the functional equivalent of such a compound.

The reaction between the compounds of the formulae (XII) and (XIII) is conveniently performed in an organic solvent such as toluene, xylene, ethyl acetate, chloroform, dichloromethane, acetonitrile or dimethylformamide. Typically the reaction is carried out at an elevated temperature for example 60-150°C.

20 The compounds of the formula (XII) may be prepared by a number of methods known in the art. For example the compounds of the formula (XII) may be prepared by the acylation of a compound of the formula (XIV):




30 wherein P^1 , R^2 , R^{10} , R^{12} , R^{13} , and R^{18} are as hereinbefore defined and P^1 is optionally substituted as hereinbefore defined with a compound of the formula (XV):



40 wherein R^{11} is as hereinbefore defined.

The compounds of the formula (XIV) may be prepared by reacting compounds of the formulae (XVI) and (VII):



50 wherein R^2 and R^{13} are as hereinbefore defined. The compounds of the formula (XVI) are known in the art and may be reacted with the compounds of the formula (VII) under conventional acylation methods known in the art.

Compounds of the formulae (VII), (XII) and (XIV) are novel and, as such, form another aspect of this invention.

55 The following biological test methods, data and Examples serve to illustrate the present invention.

Antibacterial Activity

The pharmaceutically acceptable carbapenem compounds of the present invention are useful antibacterial agents having a broad spectrum of activity in vitro against standard laboratory microorganisms, both Gram-negative and Gram-positive, which are used to screen for activity against pathogenic bacteria. The antibacterial spectrum and potency of a particular compound may be determined in a standard test system. In particular the carbapenems of the present invention show good stability to beta-lactamases and in general particularly good pharmacokinetics, especially as regards half life. In general compounds show significant improvement over imipenem.

The antibacterial properties of the compounds of the invention may also be demonstrated in vivo in conventional tests.

Carbapenem compounds have generally been found to be relatively non-toxic to warm-blooded animals, and this generalisation holds true for the compounds of the present invention. Compounds representative of the present invention were administered to mice at doses in excess of those required to afford protection against bacterial infections, and no overt toxic symptoms or side effects attributable to the administered compounds were noted.

The following results were obtained for representative compounds on a standard in vitro test system using Diagnostic Sensitivity Test. The antibacterial activity is described in terms of the minimum inhibitory concentration (MIC) determined by the agar-dilution technique with an inoculum size of 10^4 CFU/spot.

ORGANISM	MIC ($\mu\text{g/ml}$)
	EXAMPLE
	1
S. aureus	0.13
Oxford	
E. coli	0.03
DCO	
P.morganii	0.03
I + 001	
Enterobacter	0.03
cloacae P99-	
B. fragilis	0.50
AMP S	

In the following examples, which are representative of the scope:

- (a) NMR spectra were taken at 200MHz or 400MHz in DMSO- d_6 /CD₃COOD unless otherwise stated;
- (b) allyloxy means the propen-1-yloxy group $-\text{OCH}_2\text{CH}=\text{CH}_2$;

- (c) THF means tetrahydrofuran;
 (d) DMF means dimethylformamide;
 (e) DMSO means dimethylsulphoxide;
 (f) DIAD means diisopropylidiazodicarboxylate;
 (g) DEAD means diethylazodicarboxylate;
 (h) EEDQ means N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline;
 (i) TFA means trifluoroacetic acid;
 (j) evaporation of solvents was carried out under reduced pressure;
 (k) HPLC means high pressure liquid chromatography; and
 (l) temperatures are given in degrees centigrade.

Example 1

(1R,5S,6S,8R,2'S,4'S) 2-(2-(8-Carboxyquinol-6-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid disodium salt

To a solution of allyl (1R,5S,6S,8R,2'S,4'S)-2-(1-allyloxycarbonyl-2-(8-allyloxycarbonylquinol-6-ylcarbamoyl) pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate (216 mg; 0.31 mm) in CH_2Cl_2 (7 ml), was added a 0.47M aqueous solution of NaHCO_3 (7.8 ml), N-methylaniline (135 μl ; 1.24 mM) and tetrakis(triphenyl)phosphine palladium (72 mg; 0.062 mM). After stirring for 1 hour the aqueous layer was separated and purified on reverse phase silica (Nucleosil C₁₈) using a gradient of acetonitrile in water (0-10%) to give after freeze-drying the title compound as a foam (30 mg; 16.6%).

NMR: δ 1.10-1.21 (m, 6H); 1.71-1.88 (m, 1H); 2.60-2.72 (m, 1H); 2.76-2.88 (m, 1H); 3.20 (dd, 1H); 3.37-3.5 (m, 2H); 3.60-3.73 (m, 1H); 3.92-4.05 (m, 2H); 4.17 (dd, 1H); 7.75 (dd, 1H); 8.65 (d, H); 8.75 (d, 1H); 8.81 (d, 1H); 8.97 (d, 1H)

MS (+ve FAB): 571 (MH^+).

The starting material was prepared as follows:

A mixture of 2-amino-5-nitrobenzoic acid (4g, 22 mM), glycerol (8 g), arsenic acid (80% in water) (20 g), and sulphuric acid (65%) (36 ml) was heated at reflux for 3.5 hours. After addition of water (100 ml), the pH was adjusted to 8 with concentrated ammonia and then to 3.5 with acetic acid. The resulting precipitate was filtered and dried to give 8-carboxy-6-nitroquinoline (4 g; 83%).

NMR ($\text{DMSO}-d_6$): δ 7.75 (dd, 1H); 8.72 (dd, 1H); 9.00 (d, 1H); 9.07 (d, 1H); 9.37 (d, 1H).

To a suspension of 8-carboxy-6-nitroquinoline (4g; 18mM) in methanol (70 ml) was added SnCl_2 (20.4 g; 90 mM). The mixture was heated to, and maintained at 40°C until dissolution of the insoluble. After evaporation of the solvent, the residue was taken-up in a 2M aqueous solution of NaOH and purified by subjecting to chromatography on Dowex 1X2 Resin. After basification (pH3) with concentrated NH_4OH the resulting solid was further purified by subjecting to chromatography on HP20SS resin, eluting with $\text{MeOH}/\text{H}_2\text{O}$ -AcOH 1% (30.70) to give 6-amino-8-carboxyquinoline (1.2 g, 35.5%).

NMR($\text{DMSO}-d_6$): δ 7.13 (d, 1H); 7.57 (dd, 1H); 8.11 (d, 1H); 8.34 (dd, 1H); 8.67 (d, 1H).

Preparation of the side-chain pyrrolidin-4-ylthioacetate:

To a solution of (2S,4S)-1-allyloxycarbonyl-2-carboxypyrrolidin-4-ylthioacetate (1.75 g, 6.4 mM) in CH_2Cl_2 (15ml) was added SOCl_2 (5 ml; 68.5 mM). After stirring at ambient temperature for 3 hours, the solvent was evaporated and dried under reduced pressure. The product was dissolved in CH_2Cl_2 (25 ml) and the resulting solution added dropwise to a solution of 6-amino-8-carboxyquinoline (1.2 g; 6.3 mM), N-ethyl diisopropylamine (11 ml, 56.7 mM) and trimethylethylchloride (2 m; 1.57 mM). The mixture was stirred at ambient temperature overnight. After extraction with methylene chloride, the material was purified by subjecting to chromatography on HP20SS and eluting with a gradient of acetonitrile (0-4%) in $\text{H}_2\text{O}/\text{AcOH}$ 1% to give (2S,4S)-1-allyloxycarbonyl-2-(8-carboxyquinol-6-ylcarbamoyl) pyrrolidin-4-ylthioacetate (870 mg; 31%).

NMR ($\text{DMSO}-d_6$): δ 1.85-2.10 (m, 1H); 2.31 (s, 3H); 2.65-2.92 (m, 1H); 3.25-3.56 (m, 1H); 3.86-4.11 (m, 2H); 4.31-4.70 (m, 3H); 5.00-5.40 (m, 2H); 5.70-6.04 (m, 1H); 7.75 (dd, 1H); 8.63 (d, 1H); 8.76 (d, 2H); 8.96 (d, 1H).

Synthesis of (2S,4S)-1-allyloxycarbonyl-2-(8-allyloxycarbonylquinol-6-ylcarbamoyl)pyrrolidin-4-ylthioacetate:

To a solution of the product of the previous step compound (380 mg; 0.85 mM) in THF (5 ml), under argon, was added triphenylphosphine (247 mg, 0.93 mM) and DIAD (186 μl ; 0.93 mM). After stirring at 0°C for 15 minutes and at ambient temperature for 30 minutes, the resulting solution was partitioned between phosphate buffer (pH7) and ethyl acetate. The organic phase was evaporated and the residue purified by subjecting to flash chromatography and eluting with ethyl acetate/petroleum ether (65/35) to give the title compound as an oil (265 mg; 64%).

NMR ($\text{DMSO}-d_6$): δ 1.88-2.05 (m, 1H); 2.34 (s, 3H); 2.71-2.88 (m, 1H); 3.25-3.4 (m, 1H); 3.94-4.10 (m, 2H); 4.38-4.60 (3H); 4.90 (d, 2H); 5.15-5.36 (m, 3H); 5.50 (d, 1H); 5.71-6.00 (m, 1H); 6.02-6.13 (m, 1H); 7.55(dd, 1H); 8.11 (dd, 1H); 8.38 (d, 1H); 8.32-8.39 (m, 1H); 8.85 (d, 1H).

Allyl (1R,5R,6S,8R)-6-(1-hydroxyethyl)-1-methyl-2-diphenylphosphoryloxycarbapenem-3-carboxylate was prepared as follows:

To a solution of allyl (1R,5R,6S,8R)-6-(1-hydroxyethyl)-1-methyl-2-oxocarbapenem-3-carboxylate [prepared *in situ* from allyl 2-diazo-3-oxo-4-(R)-methyl-4-[(3S,4R)-3-(1-(R)-hydroxyethyl)-2-oxazetidin-4-yl]-butanoate and rhodium octanoate: see for example EP-A-208889] and di-isopropylethylamine (1.1 equivalents) in acetonitrile, at 0°C, under an argon atmosphere, was added dropwise diphenyl chlorophosphate (1.1 equivalents). The solution was stirred at ambient temperature for 30 minutes to form the corresponding 2-diphenylphosphoryloxycarbapenem.

Preparation of the protected carbapenem:

To a solution of the above thioacetate (265 mg; 0.54 mM) in ethanol (3 ml) was added at 0°C a solution of methylamine in ethanol (5M) (329 µl; 1.62 mM). After stirring at ambient temperature for 1.5 hours, the solvent was removed by evaporation and the resulting thiol dried under vacuum, dissolved in DMF (10 ml) and added to a solution of allyl (1R,5R,6S,8R)-6-(1-hydroxyethyl)-1-methyl-2-diphenylphosphoryloxycarbapenem-3-carboxylate (270 mg; 0.54 mM), tri-n-butylphosphine (134 µl; 0.54 mM), N-ethyl diisopropylamine (187 µl; 1.08 mM) and water (9.7 µl; 0.54 mM) in DMF (10 ml). The mixture was stirred at ambient temperature for 2 hours. After evaporation of the solvent, the residue was extracted with methylene chloride and purified by subjecting to flash chromatography, eluting with ethyl acetate/CH₃CN (95/5) to give allyl (1R,5S,6S,8R,2'S,4'S) (2-(1-allyloxycarbonyl-2-(8-allyloxycarbonylquinol-6-ylcarbamoyl) pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate as an oil (250 mg - 67%).

NMR (DMSO-d₆) : δ 1.14-1.23 (m, 6H); 1.86-2.05 (m, 1H); 2.75-2.92 (m, 1H); 3.20-3.40 (m, 2H); 3.47-3.63 (m, 1H); 3.90-4.09 (m, 2H); 4.12-4.30 (m, 2H); 4.4-4.65 (m, 3H); 4.84-5.57 (m, 10H); 5.72-6.18 (m, 3H); 7.60 (m, 1H); 8.13 (s, 1H); 8.40 (dd, 1H); 8.5 (s, 1H); 8.86 (dd, 1H).

Example 2

(1R,5S,6S,8R,2'S,4'S)-2-(2-(6-Carboxyquinol-8-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid disodium salt.

The title compound was prepared from the corresponding diallyl protected compound using a similar method to that described in example 1. (Yield : 31%)

NMR: δ 1.10-1.21 (m, 6H) 1.78-1.89 (m, 1H); 2.57-2.76 (m, 2H); 3.21 (dd, 1H); 3.41-3.48 (m, 1H); 3.53-3.66 (m, 2H); 3.92-4.0 (m, 1H); 4.04-4.12 (m, 1H); 4.17 (dd, 1H); 7.7 (dd, 1H); 8.35 (d, 1H); 8.57 (dd, 1H); 9.02 (dd, 1H); 9.24 (d, 1H). MS : +ve FAB : 571 (MH⁺).

The starting material was prepared as follows:

6-Carboxy-8-nitroquinoline was prepared from ethyl 4-amino-3-nitrobenzoate using the method described for 8-carboxy-6-nitroquinoline in example 1. (Yield : 61%).

NMR (DMSO-d₆) : δ 7.76 (dd, 1H); 8.57 (s, 1H); 8.72 (dd, 1H); 8.81 (s, 1H); 9.08 (dd, 1H).

To a solution of 6-carboxy-8-nitroquinoline (5.7 g; 26 mM) in THF (70 ml) was added triphenylphosphine (8.9 g; 33.8 mM), allyl alcohol (2.3 ml; 33.8 mM) and DEAD (5.35 ml; 33.8 mM). After stirring at ambient temperature for 30 minutes, the mixture was extracted with ethyl acetate and purified by subjecting to flash chromatography, eluting with ethyl acetate/petroleum ether (40/60) to give 6-allyloxycarbonyl 8-nitroquinoline (4 g; 67.7%).

NMR (CDCl₃) : δ 4.89-4.96 (m, 2H); 5.34-5.51 (m, 2H); 6.02-6.14 (m, 1H); 7.65 (dd, 1H); 8.40 (dd, 1H); 8.61 (s, 1H); 8.8 (s, 1H); 9.15 (dd, 1H).

To a solution of 6-allyloxycarbonyl-8-nitroquinoline (4 g; 15.5 mM) in methanol (80 ml) was added SnCl₂ (17.8 g; 77.5 mM). The mixture was heated at 40°C for 1 hour. After evaporation of the solvent, the residue was partitioned between an aqueous solution of NaHCO₃ (10%) and ethyl acetate. The organic phase was concentrated and purified by subjecting to flash chromatography, eluting with ethylacetate/petroleum ether (30/70) to give 8-amino-6-allyloxy-carbonylquinoline (3.4 g; 96%). NMR (CDCl₃) : δ 4.84-4.90 (m, 2H); 5.10 (s, 2H); 5.30-5.48 (m, 2H); 6.02-6.14 (m, 1H); 7.43 (dd, 1H); 7.51 (s, 1H); 7.94 (s, 1H); 8.17 (dd, 1H); 8.85 (dd, 1H).

(2S,4S) 1-Allyloxycarbonyl-2-(allyloxycarbonylquinol-8-ylcarbamoyl) pyrrolidin-4-ylthioacetate was prepared from 8-amino-6-allyloxycarbonylquinoline using a similar method to that described in example 1. (Yield : 65.3%)

NMR (DMSO-d₆) : δ 2.03-2.13 (m, 1H); 2.3 (s, 3H); 2.78-2.94 (m, 1H); 3.30-3.40 (m, 1H); 3.96-4.15 (m, 2H); 4.40-4.65 (m, 2H); 4.71-4.94 (m, 3H); 5.06-5.52 (m, 4H); 5.65-6.04 (m, 1H); 6.05-6.17 (m, 1H); 7.76 (dd, 1H); 8.47 (d, 1H); 8.68 (dd, 1H); 9.06 (s, 1H); 9.18 (s, 1H).

Preparation of the protected carbapenem:

Allyl (1R,5S,6S,8R,2'S,4'S)-2-(1-allyloxycarbonyl-2-(6-allyloxycarbonylquinol-8-yl carbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate was prepared from the product of the previous step, using a similar method to that described in example 1. (Yield : 87.5%)

NMR (DMSO-d₆) : δ 1.10-1.22 (m, 6H); 2.09-2.18 (m, 1H); 2.84-2.97 (m, 1H); 3.25 (dd, 1H); 3.36-3.6 (m, 2H); 3.93-4.03 (m, 2H); 4.13-4.21 (m, 1H); 4.25 (dd, 1H); 4.3-4.36 (m, 2H); 4.5-5.5 (m, 11H); 5.55-6.02 (m, 2H); 6.03-6.17 (m, 1H);

7.72 (dd, 1H); 8.44 (d, 1H); 8.61 (dd, 1H); 9.00 (d, 1H); 9.02 (s, 1H).

Example 3

5 (1R,5S,6S,8R,2'S,4'S) 2-(2-(7-Carboxyquinol-5-ylcarbamoyle)-pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid, disodium salt

To a solution of allyl (1R,5S,6S,8R,2'S,4'S) 2-(2-(7-carboxyquinol-5-ylcarbamoyle)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate (280 mg; 0.4 mM) in CH₂Cl₂ (4ml) was added N,N-dimethyltrimethylsilylamine (389 µl/2.4 mM) and tetrakis(triphenyl)phosphine palladium (46.8 mg; 0.04 mM). After stirring at ambient temperature for 15 minutes, the solvent was removed and the residue redissolved in water. After acidification to pH 4.5 with acetic acid, the solution was maintained at 0°C for 1 hour, then basified to pH8 and extracted with CH₂Cl₂. The aqueous layer was separated and purified by subjecting to chromatography on reverse phase silica (Nucleosil C18) using a gradient of CH₃CN in water (0-3%), to give the title compound as a foam after freeze-drying. (65 mg; 28.5%).
15 NMR: δ 1.11-1.21 (m, 6H); 1.82-1.90 (m, 1H); 2.65-2.76 (m, 1H); 2.81-2.95 (m, 1H); 3.18 (dd, 1H); 3.35-3.55 (m, 2H); 3.67-3.78 (m, 1H); 3.91-4.00 (m, 1H); 4.07-4.20 (m, 2H); 7.65 (dd, 1H); 8.42 (sbr, 2H); 8.99 (d, 1H).

MS (+ve FAB): 571 (M+H⁺)

The starting material was prepared as follows:

7-Carboxy-5-nitroquinoline was prepared from 3-amino-5-nitrobenzoic acid using a similar method to that described for 8-carboxy-6-nitroquinoline in example 1. A mixture of compounds was obtained and used in the next step without separation.

7-Allyloxycarbonyl-5-nitroquinoline was prepared from the product of the previous step using a similar method to that described for 6-allyloxycarbonyl-8-nitroquinoline in example 1. (Yield : 44%)

25 NMR (CDCl₃): δ 4.92-5 (m, 2H); 5.36-5.53 (m, 2H); 6.05-6.18 (m, 1H); 7.71 (dd, 1H); 9.06 (d, 1H); 9.13 (dd, 1H); 9.17 (d, 1H); 9.46 (dd, 1H).

5-Amino-7-allyloxycarbonylquinoline was prepared from 6-allyloxycarbonyl-8-nitroquinoline using a similar method to that described for 8-amino-6-allyloxycarbonylquinoline in example 1. (Yield : 24%)

NMR (CDCl₃): δ 4.31 (s, 2H); 4.85-4.90 (m, 2H); 5.28-5.5 (m, 2H); 6.02-6.14 (m, 1H); 7.43 (d, 1H); 7.45 (dd, 1H); 8.2 (dd, 1H); 8.31 (s, 1H); 8.97 (dd, 1H).

30 (2S,4S) 1-Allyloxycarbonyl-2-(7-allyloxycarbonylquinol-5-ylcarbamoyle)pyrrolidin-4-yl thioacetate was prepared using a similar method to that described in example 1. (Yield : 45.6%)

NMR: δ 2.05-2.15 (m, 1H); 2.35 (s, 3H); 2.81-2.97 (m, 1H); 3.32-3.43 (m, 1H); 4.00-4.13 (m, 2H); 4.53-4.71 (m, 3H); 4.85-4.97 (m, 2H); 5.07-5.55 (m, 4H); 5.84-6.01 (m, 1H); 6.05-6.20 (m, 1H); 7.68(dd, 1H); 8.23 (s, 1H); 8.51 (s, 2H); 9.03 (dd, 1H).

35 Allyl (1R,5S,6S,8R,2'S,4'S)-2-(2-(7-carboxyquinol-5-ylcarbamoyle)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate was prepared from the product of the previous step, using a similar method to that described in example 1. (Yield : 50%) NMR: δ 1.18 (d, 3H); 1.21 (d, 3H); 2.02-2.11 (m, 1H); 2.84-3.00 (m, 1H); 3.26-3.73 (m, 3H); 3.93-4.07 (m, 2H); 4.11-4.20 (m, 1H); 4.22-4.30 (m, 1H); 4.51-4.73 (m, 3H); 4.86-4.93 (m, 2H); 5.07-5.50 (m, 8H); 5.82-6.00 (m, 2H); 6.02-6.17 (m, 1H); 7.71 (dd, 1H); 8.18-8.26 (m, 1H); 8.40-8.58 (m, 1H); 8.52 (s, 1H); 9.04 (dd, 1H).

Example 4

45 (1R,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-2-quinolylcarbamoyle)pyrrolidine-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid

A solution of (1R,5S,6S,8R,2'S,4'S) 2-(1-(4-nitrobenzyloxycarbonyl)-2-(3-carboxy-2-quinolylcarbamoyle) pyrrolidine-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid (dipotassium salt) (420 mg, 0.5 mmol) in water (25 ml) was hydrogenated of atmospheric pressure over Pd/carbon (10%) (300 mg) for 1 hour. The catalyst was filtered off, the filtrate note concentrated and purified by subjecting to preparatory HPLC (Nucleosil C-18), eluant water. Concentration and freeze drying gave the title compound (90 mg, 25%).

50 NMR: δ 5 1.2 (m, 6H); 1.78 (m, 1H); 2.9 (m, 2H); 3.2 (dd, 1H); 3.4 (dq, 1H); 3.52 (m, 1H); 3.8 (m, 1H); 3.96 (dq, 1H); 4.18 (dd, 1H); 4.17 (m, 1H); 7.48 (dd, 1H); 7.72 (dd, 1H); 7.85 (d, 1H); 7.96 (d, 1H); 8.86 (s, 1H).

Ethyl 2-cyano-2-(2-nitrobenzylidene)acetate (10.5g, 48.6 mmol) was solubilized in acetic acid (30%). The solution was cooled to 10°C in an iced water bath. Zinc powder (6.35 g, 97 mmol) was added in small amounts to the reaction mixture, with stirring, the temperature being maintained below 15°C. After 1.5 hours the solvent was evaporated. The residue was purified by subjecting to silica gel chromatography, (eluant: ethyl acetate followed by CH₂Cl₂ /methanol, 90/10) to give ethyl 2-amino-1-oxo-quinolin-3-carboxylate (9.6 g, quantitative).

NMR (CDCl₃): δ 1.47 (t, 3H); 4.47 (q, 2H); 7.25-8.0 (m, 5H); 8.45 (s, 1H); 8.55 (d, 1H).

Ethyl 2-amino-1-oxoquinoline-3-carboxylate (9.2 g, 42.5 mmol) in methanol (100 ml) was treated with a 2M aqueous solution of NaOH (45ml, 90 mmol). The reaction mixture was stirred for 3 hours and followed by HPLC (Eluant: H₂O/methanol/AcOH 1/1/0.01). At the end of the reaction, the mixture was acidified (pH3, HCl 2N) and the precipitated solid filtered, washed with water, and dried under reduced pressure to give 2-amino-1-oxo-quinolin-3-carboxylic acid (7g, 87.5%).

NMR: (DMSO-d₆): δ 7.20 (s, 1H); 7.60 (t, 1H); 3.72 (d, 1H); 8.05 (d, 1H); 8.20 (s, 1H).

2-Amino-1-oxo-quinoline-3-carboxylic acid (2g, 10 mmol) in methanol (200 ml) was treated, at 0°C, with a solution of TiCl₃ (15% in water), the TiCl₃ solution being added drop by drop. The mixture was stirred at ambient temperature for 4 hours. Water was added to the crude mixture and the precipitate filtered, washed with water and dried to give 2-amino-quinolin-3-carboxylic acid (1.78 g, 97%).

NMR (DMSO-d₆ + MeOD₄ + NaOD/D₂O): δ 6.95-7.70 (M, 4M); 8.5 (S, 1H).

(2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-2-(3-carboxy-2-quinolylcarbamoyle)pyrrolidin-4-ylthioacetate.

(2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-4-acetylthio-2-carboxypyrrolidine, (1.5 g, 4 mmol) was solubilized at ambient temperature in thionyl chloride (12 ml) and stirred for 5 hours. The thionyl chloride was evaporated, and the residue solubilized in CH₂Cl₂/toluene 1/1 (40 ml). The solvent was evaporated and dried under high vacuum for 1 hour. The acid chloride thus obtained was solubilized in dry CH₂Cl₂ (10 ml) and added, under argon, to a solution of 2-amino-quinolin-3-carboxylic acid (765 mg, 4 mmol) and diisopropylethylamine (2.12 ml, 12 mmol) in DMF (anhydrous, 20 ml), at 0°C. The mixture was stirred for 12 hours at ambient temperature, concentrated to remove the methylene chloride, and the residue subjected to chromatography on a HP20SS column, eluant MeOH/H₂O/AcOH (1/100) gradient of MeOH to give the title compound (1.3 g, 60%).

NMR (DMSO d₆ + TFA-d): δ 2.0-2.25 (m, 1H); 2.3 (s, 3H); 2.65-2.95 (m, 1H); 3.20-3.60 (m, 1H); 3.80-4.35 (m, 2H); 4.95 (m, 1H) 5.20 (s, 2H); 7.4-7.7 (m, 3H); 7.8-8.25 (m, 5H); 8.95 (s, 1H)

Allyl (1R,5R,6S,8R,2'S,4'S)-2-(1-(4-Nitrobenzyloxycarbonyl)-2-(3-Carboxy-2-quinolylcarbamoyle)pyrrolidine-4-ylthio)-6-(1-hydroxy-ethyl)-1-methylcarbapenem-3-carboxylate.

(2S,4S) 1-(4-Nitrobenzyloxycarbamoyle)-2-(3-carboxy-2-quinolylcarbamoyle)pyrrolidin-4-ylthioacetate (538 mg, 1mmol) in methanol (25 ml) was treated with an aqueous solution of NaOH 1M (2.5 ml, 2.5 mmol) by slow addition, at 0°C. After 1 hour the mixture was acidified (pH3) with 6 HCl at 0°C, the solvent evaporated and residue dried under vacuum for 1 hour. This was dissolved in DHF (2 ml) and added to a solution of allyl (1R,5R,6S,8R) 6-(1-hydroxyethyl)-1-methyl-2-diphenylphosphoryloxycarbapenem-3-carboxylate (432 mg, 0.865 mmol) in DMF (5 ml), at 0°C, in the presence of diisopropylethylamine (300 ml, 1.72 mmol). The reaction mixture was stirred at ambient temperature overnight and subjected to chromatography on a HP20SS column, eluting with water/acetonitrile (gradient of acetonitrile used). The title compound (432 mg, 65%) was obtained.

1R,5R,6S,8R,2'S,4'S) 2-(1-(4-Nitrobenzyloxycarbonyl)-2-(3-carboxy-2-quinolylcarbamoyle)pyrrolidine-4-ylthio)-6-(hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid

A solution of a allyl (1R,5R,6S,8R,2'S,4'S)-2-(1-(4-nitrobenzyloxycarbonyl)-2-(3-carboxy-2-quinolylcarbamoyle)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate (432 mg, 0.565 mmol) in THF (20 ml) was treated at ambient temperature with triphenylphosphine (15 mg, 0.057 mmol) 0.46M potassium hexanoate in ethyl acetate (2.7 ml, 1.2 mmol) and tetrakis(triphenylphosphine) palladium (20 mg, 0.017 mmol) for 1 hour. Ethyl acetate (20 ml) was added to the mixture, the precipitate is filtered, washed with ethyl acetate and dried to give the title compound (420 mg, 95%).

NMR: δ 1.2 (m, 6H); 1.9 (m, 1H); 3.05 (m, 1H); 3.2 (dd, 1H); 3.35 (m, 1H); 3.5 (m, 1H); 3.85-9.1 (m, 3H); 4.15 (m, 1H); 5.0-5.4 (m, 3H); 7.5 (m, 2H); 7.7 (m, 2H); 7.75-8.0 (m, 3H); 8.25 (d, 1H); 8.85 (d, 1H).

Example 5

(1R,5S,6S,8R,2'S,4'S)-2-(2-Carboxy-4-quinolylcarbamoyle)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid

The title compound was prepared using a similar method to that described in example 4.

NMR (DMSO-d₆): δ 1.2 (m, 6H); 1.45 (m, 1H); 2.1 (m, 1H); 2.8 (m, 1H); 3.2 (dd, 1H); 3.4-3.6 (m, 2H); 3.7 (m, 1H); 3.9 (m, 2H); 4.15 (m, 1H); 7.6-8.2 (m, 4H); 8.9 (s, 1H).

2-allyloxycarbonyl-4-amino-quinoline

4-Amino-2-quinoline carboxylic acid (800 mg, 4.2 mmol) in DMF (10 ml) and K_2CO_3 (1.17 g, 8.5 mmol) was stirred at ambient temperature in the presence of allyl bromide (1.47 ml, 17 mmol) for 24 hours. The solvent was evaporated and the crude residue purified by subjecting to silico-gel chromatography, eluting with petroleum ether ethyl acetate 1/1 to give 2-allyloxycarbonyl-4-amino-quinoline (170 mg, 17%).

NMR (CDCl₃): δ 4.75-5 (m, 4H); 5.2-5.0 (m, 2H); 5.9-6.35 (m, 1H); 7.35-8.3 (m, 5H).

(2S,4S) 1-(4-Nitrobenzyloxycarbonyl)-2-(2-allyloxycarbonyl-4-quinolylcarbamoyl) pyrrolidine-4-ylthioacetate

The title compound was prepared from the product of the previous step using a similar method to that described in example 4 except using methylene chloride as the solvent.

NMR (DMSO- d_6): δ 2.1 (m, 1H); 2.4 (s, 3H); 2.9 (m, 1H); 3.4 (m, 1H); 4.0-4.2 (m, 3H); 4.8-5.5 (m, 6H); 6.1 (m, 1H); 7.4-8.8 (m, 9H).

Allyl (1R,5S,6S,8R,2'S,4'S) 2-(1-(4-Nitrobenzyloxycarbonyl)-2-(2-allyloxycarbonyl-4-quinolylcarbamoyl) pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate

The title compound was prepared from the product of the previous step using a similar method to that described in example 4.

NMR (DMSO- d_6): δ 1.2 (m, 6H); 2.1 (qt, 1H); 2.9 (m, 1H); 3.3 (dd, 1H); 3.6 (m, 2H); 4.0 (m, 2H); 4.2 (m, 2H); 4.5-4.9 (m, 5H); 5.0-5.5 (m, 6H); 5.75 (m, 2H); 7.2-8.7 (m, 9H).

(1R,5S,6S,8R,2'S,4'S)-2-(1-(4-Nitrobenzyloxycarbonyl)-2-(2-carboxy-4-quinolylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid

The title compound was prepared from the product of the previous step using a similar method to that described in example 4.

Example 6

(1R,5S,6S,2'S,4'S)-2-(2-(3-Carboxy-6-allyloxy-2-quinolyl-carbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid

A solution of (1R,5S,6S,8R,2'S,4'S) 2-(1-(4-nitrobenzyloxycarbonyl)-2-(3-carboxy-6-allyloxy-2-quinolylcarbamoyl) pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid (dipotassium salt) (185 mg, 0.23 mmol) in phosphate buffer (pH 4.7), (20 ml) was treated with zinc powder (250 mg) added in small amounts to the reaction medium. The reaction was followed by HPLC. It was completed after 1 hour. The mixture was neutralized with potassium bicarbonate and the solvent evaporated. The residue was purified by subjecting to C-18 HPLC, eluting with CH_3CN/H_2O , to give the title compound (15 mg, 10%).

NMR: δ 1.15 (m, 6H); 1.85 (m, 1H); 3.05 (m, 2H); 3.24 (dd, 1H); 3.42 (m, 1H); 3.65 (m, 1H); 3.8-4.05 (m, 2H); 4.2 (m, 1H); 4.3 (m, 1H); 4.7 (m, 1H); 5.3 (m, 1H); 5.45 (m, 1H); 6.15 (m, 1H); 7.4 (m, 2H); 7.8 (d, 1H); 8.8 (s, 1H).

allyl-2-Amino-6-allyloxy-3-quinolylcarboxylate

2-Amino-6-hydroxy-3-quinolincarboxylic acid (600 mg, 3 mmol) in DMF (5 ml) was treated with allyl bromide (520 ml, 6 mmol) and potassium carbonate (834 mg, 6 mmol). The mixture was stirred at ambient temperature overnight, water was added and the product was extracted with methylene chloride, dried, and purified by subjecting to silica gel chromatography, (eluting with ethyl ether/petroleum ether (75/25) to give allyl-2-Amino-6-allyloxy-3-quinolylcarboxylate (270 mg, 32%).

NMR (DMSO- d_6): δ 4.6 (m, 2H); 4.85 (m, 2H); 5.22 (m, 1H); 5.3 (m, 2H); 5.5 (m, 1H); 5.85-6.35 (m, 2H); 6.95 (s, 2H); 7.4 (m, 3H); 8.7 (s, 1H).

(2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-2-(3-allyloxycarbonyl-6-allyloxy-2-quinolylcarbamoyl)pyrrolidin-4-ylthioacetate

(2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-4-acetylthio-2-carboxypyrrolidine (325 mg, 0.88 mmol) and allyl-2-amino-6-allyloxy-3-quinolylcarboxylate (250 mg, 0.88 mmol) in CH_2Cl_2 (10 ml) were treated with EEDQ (240 mg, 0.97 mmol). The mixture was stirred at ambient temperature for 12 hours, the solvent evaporated, and the residue purified by subjecting to silica gel chromatography, eluting with ethyl ether to give title compound (375 mg, 67%).

NMR (DMSO- d_6): δ 2.37 (s, 3H); 2.02 (m, 1H); 2.82 (m, 1H); 3.35 (m, 1H); 3.95-4.2 (m, 2H); 4.7 (m, 5H); 5.0-5.6 (m,

6H); 6.0-6.2 (m, 2H); 7.4-7.7 (m, 4H); 7.75-7.95 (m, 2H); 8.24 (d, 1H); 8.7 (s, 1H).

Allyl (1R,5R,6S,8R,2'S,4'S)-2-(1-(4-Nitrobenzyloxycarbonyl)-2-(3-allyloxycarbonyl-6-allyloxy-2-quinolylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate

The title compound was prepared using a similar method to that of example 4.

NMR (DMSO- d_6 , AcOD- d_4): δ 1.2 (m, 6H); 2.05 (m, 1H); 2.95 (m, 1H); 3.25 (dd, 1H); 3.4 (m, 1H); 3.6 (m, 1H); 4 (m, 1H); 4.2 (m, 2H); 4.5-4.75 (m, 6H); 5-5.5 (m, 6H); 5.85 (m, 1H); 6.1 (m, 1H); 7.45 (m, 3H); 7.65 (m, 1H); 7.8 (m, 1H); 7.9 (m, 1H); 8.2 (m, 1H); 8.8 (m, 1H).

(1R,5R,6S,8R,2'S,4'S)-2-(1-(4-Nitrobenzyloxycarbonyl)-2-(3-carboxy-6-allyloxy-2-quinolylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid

The title compound was prepared using a similar method to that of example 4.

Example 7

(1R,5S,6S,8R,2'S,4'S)-2-(2-(2-Carboxyquinol-6-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid disodium salt

To a solution of allyl (1R,5S,6S,8R,2'S,4'S)-2-(2-(2-carboxyquinol-6-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate (160 mg; 0.23 mM) in CH_2Cl_2 (12 ml) was added N,N-dimethyltrimethylsilylamine (222 μ l; 0.023 mM) and tetrakis- triphenylphosphine palladium (26 mg; 0.023 mM). After stirring at ambient temperature for 15 minutes, acetic acid (100 μ l; 1.72 mM) and water (2 ml) were added. The mixture was stirred for 15 minutes, then basified to pH8. The aqueous layer was separated and purified by subjecting to chromatography on reverse phase silica (Nucleosil C18) using a gradient of CH_3CN in water (0-15%) to give the title compound as a foam after freeze-drying (38 mg; 29%).

NMR δ : 1.10-1.20 (m, 6H); 1.70-1.85 (m, 1H); 2.60-2.70 (m, 1H); 2.82 (dd, 1H); 3.20 (dd, 1H); 3.35-3.48 (m, 2H); 3.62-3.72 (m, 1H); 3.90-4.03 (m, 2H); 4.10-4.20 (m, 1H); 7.90-8.50 (m, 5H).

MS (+ve FAB): 525 (M-H).

The starting material was prepared as follows:

To a solution of 2-benzylidene-6-nitroquinoline (4.9 g; 17.7 mM) in pyridine (36.6 ml) and water (8 ml) was added portion wise $KMnO_4$ (7.5 g; 47.8 mM) keeping the temperature between 18 and 20°C. After filtration on celite, the solution was acidified (pH3), at 0°C, with H_2SO_4 (65%). The resulting precipitate was filtered, washed with water and ether and then dried to give 2-carboxy-6-nitroquinoline (1.5 g; 39%).

NMR (DMSO- d_6 + CF_3COOD): δ 8.26 (d, 1H); 8.36 (d, 1H); 8.54 (dd, 1H); 8.90 (d, 1H); 9.17 (d, 1H).

MS (CI⁺): 219 (M+H).

To a solution of 2-carboxy-6-nitroquinoline (1.5 g; 6.8 mM) in THF (30 ml) was added triphenylphosphine (2.7 g; 10.2 mM), allyl alcohol (0.7 ml; 10.2 mM) and DEAD (1.63 ml; 10.2 mM). After stirring at ambient temperature for 30 minutes, the mixture was extracted with ethyl acetate and purified by subjecting to flash chromatography, eluting with ethyl acetate/petroleum ether (40/60) to give 2-allyloxycarbonyl-6-nitroquinoline (1.2 g; 71%).

NMR ($CDCl_3$): δ 5.0-5.03 (m, 2H); 5.35-5.55 (m, 2H); 6.07-6.20 (m, 1H); 8.34 (d, 1H); 8.47 (d, 1H); 8.52-8.59 (m, 2H); 8.86 (d, 1H).

To a solution of 2-allyloxycarbonyl-6-nitroquinoline (1.25 g; 4.8 mM) in MeOH (20 ml) was added $SnCl_2 \cdot 2H_2O$ (7.65 g, 33.6 mM). After stirring at ambient temperature for 3 hours, the mixture was evaporated to dryness and the residue partitioned between an aqueous solution of NH_4OH (pH 8.5) and ethyl acetate. The organic phase was concentrated and purified by subjecting to flash chromatography, eluting with ethyl acetate/petroleum ether (65/35) to give 2-allyloxycarbonyl-6-aminoquinoline (280 mg; 28%).

NMR ($CDCl_3$): δ 4.93-5.00 (m, 2H); 5.28-5.50 (m, 2H); 6.05-6.18 (m, 1H); 6.90 (d, 1H); 7.20 (dd, 1H); 7.90 (d, 1H); 8.04-8.13 (m, 9H).

To a solution of (2S,4S)-1-allyloxycarbonyl-2-carboxypyrrolidin-4-ylthioacetate (360 mg, 1.3 mM) in CH_2Cl_2 (15 ml) was added $SOCl_2$ (865 μ l; 13 mM). After stirring at ambient temperature for 3 hours, the solvent was evaporated and dried under reduced pressure. The product was dissolved in CH_2Cl_2 (25 ml) and the resulting solution added dropwise to a solution of 2-allyloxycarbonyl-6-aminoquinoline (270 mg; 1.18 mM) and N-ethyl diisopropylamine (432 μ l; 2.47 mM) in CH_2Cl_2 (10 ml).

After stirring at ambient temperature for 2 hours, the mixture was partitioned between HCl(1N) and CH_2Cl_2 . The organic phase was concentrated and purified by subjecting to flash chromatography, eluting with ethyl acetate/petroleum ether (65/35), to give (2S,4S)-1-allyloxycarbonyl-2-(2-allyloxycarbonylquinol-6-ylcarbamoyl)pyrrolidin-4-ylthioac-

etate (420 mg; 66%).

NMR (DMSO- d_6 + CF_3COOD): δ 1.88-2.03 (m, 1H); 2.34 (s, 3H); 2.77-2.92 (m, 1H); 3.96-4.12 (m, 2H); 4.43-4.63 (m, 3H); 4.86-5.30 (m, 4H); 5.72-6.17 (m, 2H); 7.97 (d, 1H); 8.12 (d, 1H); 8.18 (d, 1H); 8.45-8.56 (m, 2H).

MS: (+ve FAB): 484 (M+H).

5 Preparation of the protected carbapenem.

To a solution of the above thioacetate (410 mg; 0.84 mM) in ethanol (5 ml) was added, at 0°C, a solution of methylamine in ethanol (5M) (1.02 ml; 5.04 mM). After stirring at ambient temperature for 2 hours, the solvent was removed by evaporation and the resulting thiol dried under vacuum, dissolved in DMF (4 ml) and added to a solution of allyl (1R,5R,6S,8R)-6-(1-hydroxyethyl)-1-methyl-2-diphenylphosphoryloxycarbapenem-3-carboxylate (420 mg; 0.84 mM), tri-n-butylphosphine (2.09 μ l; 0.84 mM), N-ethyl diisopropylamine (292 μ l; 1.68 mM) and water (15 μ l; 0.84 mM) in DMF (10 ml). The mixture was stirred at ambient temperature for 2 hours. After evaporation of the solvent, the residue was extracted with ethyl acetate and purified by subjecting to flash chromatography, eluting with ethyl acetate/CH₃CN (95/5) to give allyl (1R,5S,6S,8R,2'S,4'S)-(2-(1-allyloxycarbonyl-2-(2-allyloxycarbonylquinol-6-ylcarbamo-yl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate as a foam (160 mg; 27.5%).

NMR (DMSO- d_6): δ 1.1-1.2 (dd, 6H); 1.8-2.0 (m, 1H); 2.75-2.90 (m, 1H); 3.25-3.40 (m, 2H); 3.50-3.60 (m, 1H); 3.90-5.50 (m, 17H); 5.70-6.15 (m, 3H); 7.85-8.50 (m, 5H).

MS (+ve FAB): 691 (M+H).

Example 8

(1R,5S,6S,8R,2'S,4'S)-2-(2-(4-Carboxyquinol-8-ylcarbamo-yl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid disodium salt

The title compound was prepared from the allyl protected compound using a similar method to that described in example 7 (Yield: 30%).

NMR (DMSO + CD₃COOD): δ 1.08-1.11 (m, 6H); 1.75-1.87 (m, 1H); 2.63-2.75 (m, 1H); 3.20 (dd, 1H); 3.38-3.50 (m, 1H); 3.51-3.65 (m, 2H); 3.90-4.00 (m, 1H); 4.03-4.12 (m, 2H); 4.17 (dd, 1H); 7.56 (t, 1H); 7.71 (d, 1H); 8.27 (d, 1H); 8.71 (d, 1H); 8.90 (d, 1H).

The starting material was prepared as follows:

To a suspension of 4-carboxyquinoline (5 g; 28.9 mM) in concentrated sulphuric acid (10 ml) was added, at 65°C, fuming nitric acid (9 ml) and concentrated sulphuric acid (9 ml). After stirring at 75°C for 30 minutes, the mixture was poured onto ice; the pH adjusted to pH3 and the resulting precipitate filtered and dried to give a mixture of 4-carboxy-8-nitroquinoline and 4-carboxy-5-nitroquinoline which was not separated (4.4 g; 70%).

NMR (DMSO- d_6): δ 7.97-8.03 (m, 2H); 8.37 (d, 1H); 8.47 (d, 1H); 9.19 (d, 1H).

The above mixture was treated using a similar method to that described for the preparation 2-allyloxycarbonyl-6-nitroquinoline in example 4, to give a mixture of 4-allyloxycarbonyl-8-nitroquinoline (Yield: 23%) and 4-allyloxycarbonyl-5-nitroquinoline (Yield: 72%) which was separated by flash chromatography, eluting with ethyl acetate/petroleum ether (40/60).

NMR (DMSO- d_6): δ 4.93-5.00 (m, 2H); 5.32-5.53 (m, 2H); 6.06-6.17 (m, 1H); 7.92 (dd, 1H); 8.17 (d, 1H); 8.37 (dd, 1H); 8.88 (dd, 1H); 9.20 (d, 1H).

4-Allyloxy-8-aminocarbonylquinoline was prepared from 4-allyloxycarbonyl-8-nitroquinoline using a similar method to that described for the preparation of 2-allyloxy-6-aminocarbonylquinoline in example 7. (Yield: 92%; mp: 44-46%).

NMR (DMSO- d_6 + CF_3COOD): δ 4.94-5.00 (m, 2H); 5.32-5.53 (m, 2H); 6.05-6.20 (m, 1H); 7.61 (d, 1H); 7.71 (t, 1H); 8.09 (d, 1H); 8.34 (d, 1H); 9.12 (d, 1H).

MS: (Cl⁺): 229 (M+H).

The side-chain pyrrolidin-4-yl-thioacetate, (2S,4S)-1-allyloxycarbonyl-2-(4-allyloxycarbonylquinol-8-ylcarbamo-yl)pyrrolidin-4-ylthioacetate, was prepared from 4-allyloxycarbonyl-8-aminoquinoline using a similar method to that described in example 7. (Yield: 50%).

NMR (DMSO + CD₃COOD): δ 2.04-2.15 (m, 1H); 2.29 (s, 3H); 2.77-2.95 (m, 1H); 3.30-3.46 (m, 1H); 3.94-4.17 (m, 2H); 4.40-5.52 (m, 9H); 5.63-6.20 (m, 2H); 7.73 (t, 1H); 8.07 (d, 1H); 8.29 (d, 1H); 8.65-8.75 (m, 1H); 9.07 (d, 1H).

MS: (+ve FAB): 484 (M+H).

Preparation of the protected carbapenem:

Allyl(1R,5S,6S,8R,2'S,4'S)-2-(1-allyloxycarbonyl-2-(4-allyloxycarbonylquinol-8-ylcarbamo-yl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate was prepared from the product of the previous step, using a similar method to that described in example 7 (Yield: 30%).

NMR (DMSO- d_6 + CD₃COOD): δ 1.08-1.24 (m, 6H); 2.02-2.15 (m, 1H); 2.82-2.97 (m, 1H); 3.23 (dd, 1H); 3.47-3.57 (m, 2H); 3.82-4.05 (m, 2H); 4.10-4.30 (m, 2H); 4.47-5.50 (m, 13H); 5.62-6.18 (m, 3H); 7.73 (t, 1H); 8.05 (d, 1H); 8.27 (d, 1H); 8.65-8.75 (m, 1H); 8.97-9.10 (m, 1H).

MS: (+ve FAB): 691 (M+H).

Example 9

5 (1R,5S,6S,8R,2'S,4'S)-2-(2-(4-Carboxyquinol-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid disodium salt

The title compound was prepared from the allyl protected compound using a similar method to that described in example 7 (Yield: 24%).

10 NMR (DMSO-d₆ + CD₃COOD): δ 1.13-1.22 (m, 6H); 1.85-1.95 (m, 1H); 2.83-2.95 (m, 1H); 3.03-3.12 (m, 1H); 3.20-3.25 (m, 1H); 3.38-3.47 (m, 1H); 3.57-3.68 (m, 1H); 3.81-4.03 (m, 2H); 4.16-4.30 (m, 2H); 7.49 (d, 1H); 7.73 (t, 1H); 7.88 (d, 1H); 8.00 (d, 1H); 8.82 (d, 1H).

The starting material was prepared as follows:

15 4-Allyloxycarbonyl-5-nitroquinoline was prepared from 4-carboxy-5-nitroquinoline using a similar method to that described in example 8 (Yield: 72%).

NMR (DMSO-d₆): δ 4.74-4.81 (m, 2H); 5.28-5.47 (m, 2H); 5.93-6.07 (m, 1H); 8.0-8.07 (m, 2H); 8.42 (d, 1H); 8.59 (d, 1H); 9.23 (d, 1H).

MS (CI⁺): 259 (M+H).

20 4-Allyloxycarbonyl-5-aminoquinoline was prepared from the product of the previous step, using a similar method to that described in example 7 (Yield: 28%).

NMR (DMSO-d₆): δ 4.91-4.98 (m, 2H); 5.30-5.52 (m, 2H); 6.03-6.15 (m, 1H); 7.02 (d, 1H); 7.42-7.45 (m, 2H); 7.56 (t, 1H); 8.88 (d, 1H).

Preparation of the side-chain pyrrolidin-4-ylthioacetate:

25 (2S,4S) 1-Allyloxycarbonyl-2-(4-allyloxycarbonylquinol-5-ylcarbamoyl)pyrrolidin-4-yl thioacetate was prepared using a similar method to that described in example 7 (Yield: 53%).

NMR (DMSO-d₆ + CD₃COOD): δ 1.95-2.12 (m, 1H); 2.35 (s, 3H); 2.68-2.88 (m, 1H); 3.17-3.33 (m, 1H); 3.90-4.10 (m, 2H); 4.43-5.48 (m, 9H); 5.84-6.15 (m, 2H); 7.50-7.62 (m, 1H); 7.63-7.70 (m, 1H); 7.83-7.97 (m, 1H); 8.08 (d, 1H); 9.05 (d, 1H).

MS: (+ve FAB): 484 (M+H).

30 Preparation of the protected carbapenem:

Allyl (1R,5S,6S,8R,2'S,4'S)-2-(1-allyloxycarbonyl-2-(4-allyloxycarbonylquinol-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate was prepared from the product of the previous step, using a similar method to that described in example 7 (Yield: 25%).

35 NMR (DMSO-d₆ + CD₃COOD): δ 1.11-1.23 (m, 6H); 1.95-2.10 (m, 1H); 2.72-2.90 (m, 1H); 3.27 (dd, 1H); 3.35-3.62 (m, 2H); 3.88-4.05 (m, 2H); 4.10-4.30 (m, 2H); 4.40-5.47 (m, 13H); 5.80-6.15 (m, 3H); 7.52-7.68 (m, 2H); 7.71-7.90 (m, 1H); 8.05-8.13 (m, 1H); 8.96-9.03 (m, 1H).

MS (+ve FAB): 691 (M+H).

Example 10

40 (1R,5S,6S,8R,2'S,4'S)-2-(2-(2-Carboxyquinol-8-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid disodium salt

45 The title compound was prepared from the allyl protected compound using a method similar to that described in example 7 (Yield: 19%).

NMR (DMSO-d₆ + CD₃COOD): δ 1.06-1.11 (m, 6H); 1.78-1.88 (m, 1H); 2.64-2.77 (m, 2H); 3.20 (dd, 1H); 3.40-3.68 (m, 3H); 3.90-4.00 (m, 1H); 4.10-4.20 (m, 2H); 7.65-7.77 (m, 2H); 8.18 (d, 1H); 8.53 (d, 1H); 8.73 (d, 1H).

The starting material was prepared as follows:

50 To a solution of 2-carboxyquinoline (5 g, 29 mM) in concentrated H₂SO₄ (15 ml) was added a mixture of fuming HNO₃ (5 ml) and concentrated H₂SO₄ (10 ml). After stirring at ambient temperature for 30 minutes, the pH of the mixture was brought to pH 3.5 with a 50% aqueous solution of NaOH. The resulting solid was filtered and dried to give a mixture of 2-carboxy-8-nitroquinoline and 2-carboxy-5-nitroquinoline which was used in the next step (5 g, 79%).

NMR (DMSO-d₆ + CF₃COOD): δ 7.89 (t, 1H); 8.28 (d, 1H); 8.34-8.43 (m, 2H); 8.77 (d, 1H).

55 The above mixture was treated with allyl alcohol using a similar method to that described for the preparation of 2-allyloxycarbonyl-6-nitroquinoline to give, after chromatography, 2-allyloxycarbonyl-8-nitroquinoline (Yield: 30%) and 2-allyloxycarbonyl-5-nitroquinoline (Yield: 50%).

2-allyloxycarbonyl-8-nitroquinoline:

NMR (DMSO-d₆): δ 4.90-5.00 (m, 2H); 5.30-5.55 (m, 2H); 6.05-6.19 (m, 1H); 7.91 (t, 1H); 8.30 (d, 1H); 8.40-8.43 (m,

2H); 8.80 (d, 1H). MS: (Cl⁺): 259 (M+H).

2-Allyloxycarbonyl-8-aminoquinoline was prepared by reducing the product of the previous step, using a similar method to that described in example 7 (Yield: 88%).

NMR (DMSO-d₆): δ 4.88-4.93 (m, 2H); 5.30-5.50 (m, 2H); 6.05-6.17 (m, 1H); 6.94 (d, 1H); 7.15 (d, 1H); 7.43 (t, 1H); 8.04 (d, 1H); 8.35 (d, 1H).

Preparation of the side-chain pyrrolidin-4-ylthioacetate:

(2S,4S) 1-Allyloxycarbonyl-2-(2-allyloxycarbonylquinol-8-ylcarbamoyl)pyrrolidin-4-ylthioacetate was prepared from the product of the previous step using a similar method to that described in example 7 (Yield: 80%).

NMR (DMSO-d₆): δ 2.05-2.19 (m, 1H); 2.22 (s, 3H); 2.82-2.95 (m, 1H); 3.30-3.60 (m, 1H); 4.00-4.20 (m, 2H); 4.40-5.50 (m, 9H); 5.60-6.20 (m, 2H); 7.70-7.85 (m, 2H); 8.22 (d, 1H); 8.60-8.70 (m, 2H).

MS (+ve) FAB: 484 (M+H).

Preparation of the protected carbapenem:

Allyl (1R,5S,6S,8R,2'S,4'S)-2-(1-allyloxycarbonyl-2-(2-allyloxycarbonylquinol-8-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate was prepared from the product of the previous step, using a similar method to that described in example 7 (Yield: 45%).

NMR (DMSO-d₆ + CD₃COOD): δ 1.12-1.24 (m, 6H); 2.10-2.20 (m, 1H); 2.89-3.02 (m, 1H); 3.25 (dd, 1H); 3.45-3.55 (m, 1H); 3.62-3.73 (m, 1H); 3.96-4.28 (m, 4H); 4.48-5.52 (m, 13H); 5.58-6.23 (m, 3H); 7.68-7.80 (m, 2H); 8.18 (d, 1H); 8.58 (d, 1H); 8.67 (d, 1H).

MS (+ve) FAB: 691 (M+H).

Example 11

(1R,5S,6S,8R,2'S,4'S)-2-(2-(2-Carboxyquinol-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid disodium salt

The title compound was prepared from the allyl protected compound using a similar method to that described in example 7 (Yield: 33%).

NMR (DMSO-d₆ + CD₃COOD): δ 1.13-1.23 (m, 6H); 1.83-1.92 (m, 1H); 2.67-2.77 (m, 1H); 2.85-2.95 (m, 1H); 3.22 (dd, 1H); 3.40-3.57 (m, 2H); 3.68-3.78 (m, 1H); 3.93-4.03 (m, 1H); 4.05-4.21 (m, 2H); 7.84 (t, 1H); 7.94-8.05 (m, 2H); 8.25 (d, 1H); 8.51 (d, 1H).

The starting material was prepared as follows:

2-Allyloxycarbonyl-5-nitroquinoline was obtained as described in example 10 (Yield: 50%).

NMR (DMSO-d₆): δ 4.90-5.00 (m, 2H); 5.30-5.55 (m, 2H); 6.05-6.19 (m, 1H); 8.06 (t, 1H); 8.36 (d, 1H); 8.55-8.63 (m, 2H); 9.05 (d, 1H). MS (Cl⁺): 259 (M+H).

2-Allyloxycarbonyl-5-aminoquinoline was prepared by reducing the product of the previous step, using a similar method to that described in example 7 (Yield: 65%).

NMR (DMSO-d₆): δ 4.83-4.93 (m, 2H); 5.28-5.50 (m, 2H); 6.03-6.15 (m, 1H); 6.82 (d, 1H); 7.31 (d, 1H); 7.53 (t, 1H); 7.95 (d, 1H); 8.71 (d, 1H).

MS: (Cl⁺): 229 (M+H).

Preparation of the side-chain pyrrolidin-4-ylthioacetate:

(2S,4S) 1-Allyloxycarbonyl-2-(2-allyloxycarbonylquinol-5-ylcarbamoyl)pyrrolidin-4-ylthioacetate was prepared using a similar method to that described in example 7 (Yield: 63%).

NMR (DMSO-d₆ + CD₃COOD): δ 1.98-2.13 (m, 1H); 2.35 (s, 3H); 2.80-2.98 (m, 1H); 3.27-3.43 (m, 1H); 3.96-4.11 (m, 2H); 4.50-4.68 (m, 3H); 4.86-5.52 (m, 6H); 5.84-6.20 (m, 2H); 7.73-7.92 (m, 2H); 8.05 (d, 1H); 8.16 (d, 1H); 8.50-8.72 (m, 1H).

MS (+ve FAB): 484 (M+H).

Preparation of the protected carbapenem:

Allyl (1R,5S,6S,8R,2'S,4'S)-2-(1-allyloxycarbonyl-2-(2-allyloxycarbonylquinol-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate was prepared from the product of the previous step, using a similar method to that described in example 7 (Yield: 63%).

NMR: (DMSO-d₆ + CD₃COOD): δ 1.17-1.24 (m, 6H); 2.00-2.14 (m, 1H); 2.82-3.00 (m, 1H); 3.28 (dd, 1H); 3.32-3.62 (m, 2H); 3.94-4.09 (m, 2H); 4.12-4.30 (m, 2H); 4.53-5.52 (m, 13H); 5.83-6.20 (m, 3H); 7.76-7.92 (m, 2H); 8.08 (d, 1H); 8.18 (d, 1H); 8.52-8.71 (m, 1H).

MS (+ve FAB): 691 (M+H).

Example 12

(1R,5S,6S,8R,2'S,4'S)-2-(2-(4-Carboxyquinol-2-ylcarbamoylethio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid disodium salt

The title compound was prepared from the allyl protected compound using a similar method to that described in example 7 (Yield: 28%).

NMR (DMSO- d_6 + CD_3COOD): δ 1.10-1.21 (m, 6H); 1.80-1.88 (m, 1H); 2.65-2.86 (m, 2H); 3.20 (dd, 1H); 3.35-3.55 (m, 2H); 3.62-3.76 (m, 1H); 3.90-4.01 (m, 1H); 4.05-4.20 (m, 2H); 7.52 (t, 1H); 7.62 (t, 1H); 7.86 (d, 1H); 8.51-8.62 (m, 2H).

MS: (ES⁺): 527 (M+H).

Preparation of the side-chain pyrrolidin-4-ylthioacetate:

To a solution of (2S,4S)-1-allyloxycarbonyl-2-carboxypyrrolidin-4-yl thioacetate (1.45 g, 5.3 mM) in CH_2Cl_2 (15 ml) was added $SOCl_2$ (5 ml, 68.5 mM). After stirring at ambient temperature for 3 hours, the solvent was evaporated and dried under reduced pressure. The product was dissolved in CH_2Cl_2 (25 ml) and the resulting solution added dropwise to a solution of 2-amino-4-carboxyquinoline (1 g; 5.3 mM), N-ethyl diisopropylamine (4.5 ml, 26.5 mM) and trimethyl-ethylchloride (2.2 ml, 17.8 mM). The mixture was stirred at ambient temperature overnight. After extraction with methylene chloride, the material was used in the next step without further purification.

NMR (DMSO- d_6 + CD_3COOD): δ 1.85-2.00 (m, 1H); 2.30 (s, 3H); 2.68-2.90 (m, 1H); 3.23-3.47 (m, 1H); 3.86-4.05 (m, 2H); 4.40-4.58 (m, 3H); 5.04-5.37 (m, 2H); 5.69-6.00 (m, 1H); 7.60 (t, 1H); 7.77 (t, 1H); 7.88 (d, 1H); 8.60 (d, 1H); 8.68-8.80 (m, 1H).

(2S,4S)-1-Allyloxycarbonyl-2-(2-carboxyquinol-4-yl carbamoylethio)pyrrolidin-4-ylthioacetate was converted to (2S,4S)-1-allyloxycarbonyl-2-(2-allyloxycarbonylquinol-4-ylcarbamoylethio)pyrrolidin-4-ylthioacetate using a similar method to that used in the protecting step described for preparation of 2-allyloxycarbonyl-6-nitroquinoline in example 7 (Yield: 57%).

NMR (DMSO- d_6 + CD_3COOD): δ 1.85-2.03 (m, 1H); 2.35 (s, 3H); 2.72-2.90 (m, 1H); 3.12-3.38 (m, 1H); 3.90-4.11 (m, 2H); 4.41-4.74 (m, 3H); 4.88-5.50 (m, 6H); 5.70-6.20 (m, 2H); 7.63 (t, 1H); 7.82 (t, 1H); 7.94 (d, 1H); 8.55 (d, 1H); 8.73-8.87 (m, 1H).

MS (+ve FAB): 484 (M+H).

Preparation of the protected carbapenem:

Allyl (1R,5S,6S,8R,2'S,4'S)-2-(1-allyloxycarbonyl-2-(4-allyloxycarbonylquinol-2-ylcarbamoylethio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate was prepared from the product of the previous step, using a similar method to that described in example 7 (Yield: 75%).

NMR (DMSO- d_6 + CD_3COOD): δ 1.10-1.22 (m, 6H); 1.85-1.98 (m, 1H); 2.76-2.92 (m, 1H); 3.25-3.37 (m, 2H); 3.48-3.62 (m, 1H); 3.90-4.06 (m, 2H); 4.10-4.28 (m, 2H); 4.40-5.50 (m, 13H); 5.70-6.18 (m, 3H); 7.64 (t, 1H); 7.82 (t, 1H); 7.94 (d, 1H); 8.55 (d, 1H); 8.76-8.86 (m, 1H).

MS (+ve FAB): 691 (M+H).

Example 13

(1R,5S,6S,8R,2'S,4'S)-2-(2-(7-Carboxy-2,3-dimethylquinoxalin-5-ylcarbamoylethio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid disodium salt

The title compound was prepared from the allyl protected compound using a similar method to that described in example 7 (Yield: 18%).

NMR (DMSO- d_6 + CD_3COOD): δ 1.00-1.10 (m, 6H); 1.70-1.85 (m, 1H); 2.59-2.69 (m, 8H); 3.10 (dd, 1H); 2.28-3.40 (m, 1H); 3.45-3.58 (m, 2H); 3.81-3.92 (m, 1H); 3.97-4.03 (m, 1H); 4.08 (dd, 1H); 8.10 (s, 1H); 9.00 (s, 1H).

MS (-ve FAB): 554 (M-H).

The starting material was prepared as follows:

To a solution of 4-amino-3,5-dinitrobenzoic acid (2 g; 8.8 mM) in THF (30 ml) was added triphenylphosphine (3 g; 11.44 mM) allyl alcohol (778 μ l; 11.44 mM) and DEAD (18 ml; 11.44 mM).

After stirring at ambient temperature for 30 minutes, the mixture was extracted with ethyl acetate and purified by subjecting to flash chromatography, eluting with CH_2Cl_2 , to give allyl 4-amino-3,5-dinitrobenzoate (Yield: 100%).

NMR (DMSO- d_6): δ 5.81 (m, 2H); 5.20-5.46 (m, 2H); 6.00-6.17 (m, 1H); 8.66-8.86 (m, 4H).

To a suspension of the above compound (1.5 g; 5.6 mM) in EtOH (20 ml) was added a solution of ammonium sulphide (20%, 18 ml). After heating at reflux for 30 minutes, the mixture was evaporated to dryness and the residue taken up with water. The resulting solid was treated with MeOH and the insoluble material removed by filtration. After evaporation to dryness, allyl 3,4-diamino-5-nitrobenzoate was obtained as a solid (850 mg; 64%).

NMR (DMSO- d_6): δ 4.73-4.78 (m, 2H); 5.23-5.42 (m, 2H); 5.97-6.18 (m, 1H); 7.32 (d, 1H); 8.02 (d, 1H).

MS: (Cl⁺): 238 (M+H).

A solution of the above compound (0.5 g; 2.1 mM) and biacetyl (0.258 ml; 2.94 mM) in ethanol (25 ml) was heated at reflux for 7 hours. After filtration of the insoluble material, the compound was purified by flash chromatography, eluting with CH₂Cl₂, to give 7-allyloxycarbonyl-2,3-dimethyl-5-nitroquinoxaline (348 mg; 58%).

NMR (CDCl₃): δ 2.77-2.85 (m, 6H); 4.90-4.95 (m, 2H); 5.33-5.50 (m, 2H); 6.00-6.13 (m, 1H); 8.59 (d, 1H); 8.90 (d, 1H). MS (Cl⁺): 288 (M+H).

7-Allyloxycarbonyl-5-amino-2,3-dimethylquinoxaline was prepared from the above compound using a similar method to that described for the preparation of 6-amino-2-allyloxycarbonylquinoline in example 7 (Yield: 100%).

NMR (CDCl₃): δ 2.68-2.77 (m, 6H); 4.80-4.90 (m, 2H); 5.25-5.50 (m, 2H); 6.00-6.13 (m, 1H); 7.46 (d, 1H); 8.07 (d, 1H). MS (Cl⁺): 258 (M+H).

Preparation of the side-chain pyrrolidin-4-ylthioacetate:

(2S,4S) 1-Allyloxycarbonyl-2-(7-allyloxycarbonyl-2,3-dimethylquinoxalin-5-ylcarbamoyl)pyrrolidin-4-ylthioacetate was prepared using a similar method to that described in example 7 (Yield: 80%).

NMR (DMSO-d₆ + CF₃COOD): δ 2.03-2.20 (m, 1H); 2.30-2.95 (m, 1H); 2.75 (s, 3H); 2.79 (s, 3H); 3.33 (m, 1H); 4.00-4.17 (m, 2H); 4.45-5.50 (m, 9H); 5.65-6.18 (m, 2H); 8.26 (d, 1H); 9.00-9.15 (m, 1H).

MS (+ve FAB): 513 (M+H).

Preparation of the protected carbapenem:

Allyl(1R,5S,6S,8R,2'S,4'S)-2-(1-allyloxycarbonyl-2-(7-allyloxycarbonyl-2,3-dimethylquinoxalin-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate was prepared from the product of the previous step, using a similar method to that described in example 7 (Yield: 20%).

NMR (DMSO-d₆ + CD₃COOD): δ 1.08-1.25 (m, 6H); 2.07-2.20 (m, 1H); 2.63-2.80 (m, 6H); 2.80-3.00 (m, 1H); 3.25 (dd, 1H); 3.50 (m, 2H); 3.90-4.30 (m, 5H); 4.40-5.50 (m, 12H); 5.60-6.20 (m, 3H); 8.27 (s, 1H); 9.00-9.13 (m, 1H).

MS (+ve FAB): 720 (M+H).

Example 14

(1R,5S,6S,8R,2'S,4'S)-2-(2-(4-Carboxyquinazolin-2-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid disodium salt

The title compound was prepared from the allyl protected compound using a similar method to that described in example 7 (Yield: 15%).

NMR: (DMSO-d₆ + CD₃COOD): δ 1.05-1.25 (m, 6H); 1.70-1.80 (m, 1H); 2.60-2.85 (m, 2H); 3.15 (dd, 1H); 3.25-3.50 (m, 2H); 3.55-3.70 (m, 1H); 3.90-4.00 (m, 1H); 4.00-4.20 (m, 2H); 7.50 (m, 1H); 7.75 (d, 1H); 7.85 (m, 1H); 8.48 (d, 1H). MS -ve FAB: 526 (M-H).

The starting material was prepared as follows:

4-Allyloxycarbonyl-2-aminoquinazoline was prepared from 2-amino-4-carboxyquinazoline using a similar method to that used in the protecting step described in example 7 (Yield: 42%).

NMR (DMSO-d₆): δ 4.91-4.98 (m, 2H); 5.33-5.49 (m, 2H); 6.03-6.13 (m, 1H); 7.16-7.30 (m, 1H); 7.50 (d, 1H); 7.60 (m, 1H); 7.90 (d, 1H).

Preparation of the side-chain pyrrolidin-4-ylthioacetate:

(2S,4S)-1-Allyloxycarbonyl-2-(4-allyloxycarbonylquinazolin-2-ylcarbamoyl)pyrrolidin-4-ylthioacetate was prepared using a method to that described in example 7.

NMR (DMSO-d₆): δ 1.90-2.00 (m, 1H); 2.33 (s, 3H); 2.80-3.00 (m, 1H); 3.20-3.45 (m, 1H); 3.90-4.15 (m, 2H); 4.40-4.55 (m, 1H); 4.90-5.55 (m, 8H); 5.80-6.95 (m, 2H); 7.20-8.40 (m, 4H).

Preparation of the protected carbapenem:

Allyl(1R,5S,6S,8R,2'S,4'S)-2-(1-allyloxycarbonyl-2-(4-allyloxycarbonylquinazolin-2-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate was prepared from the product of the previous step, using a similar method to that described in example 7 (Yield: 23%).

NMR (DMSO-d₆ + CD₃COOD): δ 1.08-1.25 (m, 6H); 1.80-2.00 (m, 1H); 2.80-3.05 (m, 1H); 3.20-3.70 (m, 3H); 3.85-4.30 (m, 4H); 4.40-5.55 (m, 13H); 5.70-6.20 (m, 3H); 7.70 (m, 1H); 7.90-8.15 (m, 2H); 8.30 (d, 1H).

MS (+ve FAB): 692 (M+H).

Example 15

(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxyisoquinol-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid disodium salt

The title compound was prepared from the allyl protected compound using a similar method to that described in

example 7 (Yield: 30%).

NMR (DMSO- d_6 + CD_3COOD): δ 1.14-1.23 (m, 6H); 1.82-1.94 (m, 1H); 2.68-2.80 (m, 1H); 2.82-2.92 (m, 1H); 3.21 (dd, 1H); 3.38-3.58 (m, 2H); 3.64-3.78 (m, 1H); 3.93-4.02 (m, 1H); 4.15-4.22 (m, 2H); 7.83 (t, 1H); 8.04 (d, 1H); 8.25 (d, 1H); 8.64 (s, 1H); 9.40 (s, 1H).

The starting material was prepared as follows:

3-Carboxy-5-nitroisoquinoline was prepared from 3-carboxyisoquinoline using a method similar to that used for the preparation of 2-carboxy-8-nitroquinoline in example 10 (Yield: 93%).

NMR (DMSO- d_6 + CF_3COOD): δ 8.04 (t, 1H); 8.71 (d, 1H); 8.77 (d, 1H); 9.10 (s, 1H); 9.64 (s, 1H).

3-Allyloxycarbonyl-5-nitroisoquinoline was obtained from the product of the previous step using a similar method to that described for the preparation of 2-allyloxycarbonyl-6-nitroquinoline in example 7 (Yield: 45%).

NMR (DMSO- d_6): δ 4.90-4.96 (m, 2H); 5.28-5.50 (m, 2H); 6.05-6.17 (m, 1H); 8.06 (t, 1H); 8.72 (d, 1H); 8.78 (d, 1H); 9.14 (s, 1H); 9.65 (s, 1H).

3-Allyloxycarbonyl-5-aminoisoquinoline was prepared using a similar method to that described for the preparation of 2-allyloxycarbonyl-6-aminoquinoline in example 7 (Yield: 90%). NMR (DMSO- d_6): δ 4.80-4.95 (m, 2H); 5.23-5.50 (m, 2H); 6.04-6.17 (m, 1H); 6.95 (d, 1H); 7.30 (d, 1H); 7.51 (t, 1H); 8.82 (s, 1H); 9.15 (s, 1H).

Preparation of the side-chain pyrrolidin-4-ylthioacetate:

(2S,4S) 1-Allyloxycarbonyl-2-(3-allyloxycarbonylisoquinol-5-ylcarbamoyl)pyrrolidin-4-ylthioacetate was prepared using a similar method to that described in example 7 (Yield: 71%).

NMR (DMSO- d_6 + CD_3COOD): δ 2.00-2.13 (m, 1H); 2.33 (s, 3H); 2.80-2.87 (m, 1H); 3.30-3.43 (m, 1H); 3.98-4.13 (m, 2H); 4.50-4.73 (m, 3H); 4.82-5.53 (m, 6H); 5.78-6.17 (m, 2H); 7.82 (t, 1H); 7.95-8.05 (m, 1H); 8.06 (d, 1H); 8.73 (s, 1H); 9.39 (s, 1H).

MS: (+ve FAB): 484

Preparation of the protected carbapenem:


Allyl(1R,5S,6S,8R,2'S,4'S)-2-(1-allyloxycarbonyl-2-(3-allyloxycarbonylisoquinol-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate was prepared from the product of the previous step, using a similar method to that described in example 7 (Yield: 43%).

NMR (DMSO- d_6 + CD_3COOD): δ 1.10-1.23 (m, 6H); 1.95-2.10 (m, 1H); 2.82-2.97 (m, 1H); 3.25 (dd, 1H); 3.28-3.63 (m, 2H); 3.90-4.04 (m, 2H); 4.13-4.22 (m, 1H); 4.23-4.30 (m, 1H); 4.50-5.50 (m, 13H); 5.75-6.18 (m, 3H); 7.85 (t, 1H); 8.02-8.15 (m, 1H); 8.62-8.83 (m, 2H); 9.42 (s, 1H).

MS (+ve FAB): 691 (M+H).

Claims

1. A compound of the formula (I)




wherein:

R^1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl;

R^2 is hydrogen or C_{1-4} alkyl;


R^3 is hydrogen or C_{1-4} alkyl;

P^1 is of the formula:



and one or two of A,B,C,D,E,F,G and H, are nitrogen and the remainder are CH; and P¹ is bonded to the nitrogen of the linking carbamoyl group by a carbon atom, in either ring, is substituted by the carboxy group on a carbon atom, in either ring, and is optionally further substituted, on a carbon atom, in either ring, by up to three substituents selected from halo, cyano, C₁₋₄alkyl, nitro, hydroxy, carboxy, C₁₋₄alkoxy, trifluoromethyl, C₁₋₄alkoxycarbonyl, amino, C₁₋₄alkylamino, di-C₁₋₄alkylamino, C₁₋₄alkylS(O)_n- (wherein n is 0-2), C₁₋₄alkanoylamino, C₁₋₄alkanoyl(N-C₁₋₄alkyl)amino, carbamoyl, C₂₋₆alkenyloxy, C₁₋₄alkylcarbamoyl and di-C₁₋₄alkylcarbamoyl; or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

2. A compound according to claim 1 wherein R² is methyl.
3. A compound according to claim 1 wherein R¹ is 1-hydroxyethyl.
4. A compound according to any one of claims 1 to 3 of the formula (IV):




wherein P¹, R³, and optional substituents on P¹ are as defined in claim 1.

5. A compound according to claim 4 wherein optional substituents on P¹ are selected from halo, cyano, C₁₋₄alkyl, nitro, hydroxy, carboxy, C₁₋₄alkoxy, carbamoyl, amino, trifluoromethyl and allyloxy.
6. A compound according to claim 1 which is
 - (1R,5S,6S,8R,2'S,4'S)-2-(2-(8-carboxyquinol-6-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methyl-carbapenem-3-carboxylic acid; and
 - (1R,5S,6S,8R,2'S,4'S)-2-(2-(6-carboxyquinol-8-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methyl-carbapenem-3-carboxylic acid;
 - (1R,5S,6S,8R,2'S,4'S)-2-(2-(7-carboxyquinol-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methyl-carbapenem-3-carboxylic acid;
 - (1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyquinol-2-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methyl-carbapenem-3-carboxylic acid;
 - (1R,5S,6S,8R,2'S,4'S)-2-(2-(2-carboxyquinol-4-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methyl-carbapenem-3-carboxylic acid;
 - (1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-6-allyloxyquinol-2-ylcarbamoyl)-pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;
 - (1R,5S,6S,8R,2'S,4'S)-2-(2-(2-carboxyquinol-6-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methyl-carbapenem-3-carboxylic acid;
 - (1R,5S,6S,8R,2'S,4'S)-2-(2-(4-carboxyquinol-8-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methyl-carbapenem-3-carboxylic acid;
 - (1R,5S,6S,8R,2'S,4'S)-2-(2-(4-carboxyquinol-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methyl-carbapenem-3-carboxylic acid;
 - (1R,5S,6S,8R,2'S,4'S)-2-(2-(2-carboxyquinol-8-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methyl-

carbapenem-3-carboxylic acid;
 (1R,5S,6S,8R,2'S,4'S)-2-(2-(2-carboxyquinol-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methyl-
 carbapenem-3-carboxylic acid;
 (1R,5S,6S,8R,2'S,4'S)-2-(2-(4-carboxyquinol-2-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methyl-
 carbapenem-3-carboxylic acid;
 (1R,5S,6S,8R,2'S,4'S)-2-(2-(7-carboxy-2,3-dimethylquinoxalin-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;
 (1R,5S,6S,8R,2'S,4'S)-2-(2-(4-carboxyquinazolin-2-ylcarbamoyl)-pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-
 1-methylcarbapenem-3-carboxylic acid;
 (1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyisoquinol-5-ylcarbamoyl)-pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-
 1-methylcarbapenem-3-carboxylic acid;

and pharmaceutically-acceptable salts thereof.

7. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 6 and a pharmaceutically acceptable carrier.
8. A process for preparing a compound according to claim 1 which comprises deprotecting a compound of the formula (V):




wherein R^2 is as defined in claim 1; R^{10} is a group R^3 (as defined in claim 1) or an amino protecting group; R^{13} is a group R^1 (as defined in claim 1), protected hydroxymethyl or 1-(protected hydroxy)ethyl; R^{11} is hydrogen or a carboxy protecting group; R^{12} is hydrogen or an amino protecting group; P^1 is as defined in claim 1; R^{18} is a carboxy group or a protected carboxy group and wherein any optional substituent on P^1 is as defined in claim 1 and is optionally protected; and wherein at least one protecting group is present; and thereafter if necessary;

- (i) forming a pharmaceutically acceptable salt,
 (ii) esterifying to form an *in vivo* hydrolysable ester.

9. A process for preparing a compound according to claim 1 or a compound of the formula (V) as defined in claim 8 which comprises:

a) reacting compounds of the formulae (VI) and (VII):



wherein P^1 , R^2 , R^{10} , R^{11} , R^{12} , R^{13} and R^{18} are as defined in claim 8, optional substituents on P^1 are as defined in claim 8 and L is a leaving group, or
 b) cyclising a compound of the formula (VIII):



15

- 20


25



wherein P^1 , R^2 , R^{10} - R^{13} and R^{18} are as defined in claim 8 and R^{17} is a protecting group.


Patentansprüche

1. Verbindung der Formel (I)



in der

R^1 eine 1-Hydroxyethyl-, 1-Fluorethyl- oder Hydroxymethylgruppe ist;
 R^2 ein Wasserstoffatom oder ein C_{1-4} -Alkylrest ist;
 R^3 ein Wasserstoffatom oder ein C_{1-4} -Alkylrest ist;
 P^1 die Formel




hat und einer oder zwei der Reste A, B, C, D, E, F, G und H Stickstoffatome sind und die restlichen für CH stehen; und P^1 über ein Kohlenstoffatom in einem der beiden Ringe an das Stickstoffatom des verknüpfenden Carbamoylrestes gebunden ist, an einem Kohlenstoffatom in einem der beiden Ringe mit der Carboxygruppe substituiert ist und gegebenenfalls in beiden Ringen an Kohlenstoffatomen mit bis zu drei Substituenten weiter substituiert ist, welche ausgewählt sind aus Halogenatom, Cyanogruppe, C_{1-4} -Alkylrest, Nitro-, Hydroxy-, Carboxygruppe, C_{1-4} -Alkoxyrest, Trifluormethylgruppe, C_{1-4} -Alkoxy-carbonylrest, Aminogruppe, C_{1-4} -Alkylaminorest, Di- C_{1-4} -alkylaminorest, C_{1-4} -Alkyl-S(O) $_n$ -rest (wobei n 0-2 ist), C_{1-4} -Alkanoylaminorest, C_{1-4} -Alkanoyl(N- C_{1-4} -alkyl)aminorest, Carbamoylrest, C_{2-6} -Alkenyloxyrest, C_{1-4} -Alkylcarbamoylrest und Di- C_{1-4} -alkylcarbamoylrest;

oder ein pharmazeutisch verträgliches Salz oder ein *in vivo* hydrolysierbarer Ester davon.

2. Verbindung nach Anspruch 1, wobei R^2 eine Methylgruppe ist.

3. Verbindung nach Anspruch 1, wobei R^1 eine 1-Hydroxyethylgruppe ist.

4. Verbindung nach einem der Ansprüche 1 bis 3 mit der Formel (IV)



in der P¹, R³ und eventuelle Substituenten an P¹ wie in Anspruch 1 definiert sind.

5. Verbindung nach Anspruch 4, wobei eventuelle Substituenten an P¹ ausgewählt sind aus Halogenatom, Cyano-
gruppe, C₁₋₄-Alkylrest, Nitro-, Hydroxy-, Carboxygruppe, C₁₋₄-Alkoxyrest, Carbamoylrest, Aminogruppe, Trifluor-
methylgruppe und Allyloxyrest.


6. Verbindung nach Anspruch 1, bei der es sich handelt um

(1R,5S,6S,8R,2'S,4'S)-2-(2-(8-Carboxychinol-6-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carbonsäure;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(6-Carboxychinol-8-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carbonsäure;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(7-Carboxychinol-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carbonsäure;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxychinol-2-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carbonsäure;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(2-Carboxychinol-4-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carbonsäure;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-6-allyloxychinol-2-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carbonsäure;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(2-Carboxychinol-6-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carbonsäure;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(4-Carboxychinol-8-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carbonsäure;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(4-Carboxychinol-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carbonsäure;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(2-Carboxychinol-8-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carbonsäure;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(2-Carboxychinol-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carbonsäure;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(4-Carboxychinol-2-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carbonsäure;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(7-Carboxy-2,3-dimethylchinoxalin-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carbonsäure;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(4-Carboxychinazolin-2-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carbonsäure;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxyisochinol-5-ylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carbonsäure;

sowie pharmazeutisch verträgliche Salze davon.

7. Arzneimittel, welches eine Verbindung nach einem der Ansprüche 1 bis 6 und einen pharmazeutisch verträglichen Träger umfaßt.

8. Verfahren zur Herstellung einer Verbindung nach Anspruch 1, umfassend das Entfernen der Schutzgruppen von einer Verbindung der Formel (V)




wobei R² wie in Anspruch 1 definiert ist; R¹⁰ für einen Rest R³ (wie in Anspruch 1 definiert) oder eine Amino-

Schutzgruppe steht; R^{13} für einen Rest R^1 (wie in Anspruch 1 definiert), eine geschützte Hydroxymethylgruppe oder geschützte 1-Hydroxyethylgruppe steht; R^{11} ein Wasserstoffatom oder eine Carboxy-Schutzgruppe ist; R^{12} ein Wasserstoffatom oder eine Amino-Schutzgruppe ist; P^1 wie in Anspruch 1 definiert ist; R^{18} eine Carboxygruppe oder eine geschützte Carboxygruppe ist. und wobei jeder eventuelle Substituent an P^1 wie in Anspruch 1 definiert und gegebenenfalls geschützt ist; und wobei mindestens eine Schutzgruppe vorhanden ist; sowie danach falls erforderlich:

- (i) Erzeugen eines pharmazeutisch verträglichen Salzes.
- (ii) Veresterung zu einem *in vivo* hydrolysierbaren Ester.


9. Verfahren zur Herstellung einer Verbindung nach Anspruch 1 oder einer wie in Anspruch 8 definierten Verbindung der Formel (V), umfassend:

a) Umsetzen von Verbindungen der Formeln (VI) und (VII)



wobei P^1 , R^2 , R^{10} , R^{11} , R^{12} , R^{13} und R^{18} wie in Anspruch 8 definiert sind, eventuelle Substituenten an P^1 wie in Anspruch 8 definiert sind und L eine Abgangsgruppe ist, oder




b) Cyclisieren einer Verbindung der Formel (VIII)



wobei P^1 , R^2 , R^{10} , R^{11} , R^{12} , R^{13} und R^{18} wie in Anspruch 8 definiert sind, eventuelle Substituenten an P^1 wie in Anspruch 8 definiert sind und R^{14} , R^{15} und R^{16} unabhängig voneinander aus C_{1-6} -Alkoxy-, Aryloxy-, Di- C_{1-6} -alkylamino- und Diarylaminoresten ausgewählt sind oder zwei beliebige der Reste R^{14} - R^{16} für o-Phenylendioxygruppen stehen oder einer der Reste R^{14} - R^{16} eine C_{1-4} -Alkyl-, Allyl-, Benzyl- oder Phenylgruppe ist und die anderen beiden Bedeutungen unabhängig voneinander aus C_{1-4} -Alkyl-, Trifluormethyl- oder Phenylgruppen ausgewählt sind, wobei jede Phenylgruppe gegebenenfalls mit C_{1-3} -Alkyl- oder C_{1-3} -Alkoxyresten substituiert ist; und wobei jede funktionelle Gruppe gegebenenfalls geschützt ist; sowie danach falls erforderlich

- (i) Entfernen jeglicher Schutzgruppen;
- (ii) Erzeugen eines pharmazeutisch verträglichen Salzes;
- (iii) Veresterung zu einem *in vivo* hydrolysierbaren Ester.

10. Verbindung der Formel (V) wie in Anspruch 8 definiert, der Formel (VII) oder (VIII) wie in Anspruch 9 definiert oder der Formel (IX), (XII) oder (XIV)




35

wobei P¹, R², R¹⁰-R¹³ und R¹⁸ wie in Anspruch 8 definiert sind und R¹⁷ eine Schutzgruppe ist.

Revendications


40

1. Composé de formule (I)



dans laquelle :


- R¹ représente un groupe 1-hydroxyéthyle, 1-fluoroéthyle, ou hydroxyméthyle ;
- R² représente un atome d'hydrogène ou un groupe alkyle C₁₋₄ ;
- R³ représente un atome d'hydrogène ou un groupe alkyle C₁₋₄ ;
- P¹ a pour formule:



- et un ou deux de A, B, C, D, E, F, G, ou H représentent un atome d'azote et les autres représentent CH ; et
- P¹ est lié à l'azote du groupe de liaison carbamoyl par un atome de carbone dans l'un ou l'autre cycle, est substitué par le groupe carboxy sur un atome de carbone dans l'un ou l'autre cycle, et est éventuellement encore substitué sur un atome de carbone dans l'un ou l'autre cycle, par jusque trois substituants choisis parmi les groupes halo, cyano, alkyle C₁₋₄, nitro, hydroxy, carboxy, alcoxy C₁₋₄, trifluorométhyle, alcoxy C₁₋₄ carboxyle, amino, alkyl C₁₋₄ amino, dialkyl C₁₋₄ amino, alkyl C₁₋₄ S(O)_n- (dans lequel n est égal à 0, 1, ou 2), alcanoyl C₁₋₄ amino, alcanoyl C₁₋₄ (N-alkyl C₁₋₄) amino, carbamoyl, alkényloxy C₂₋₆, alkyl C₁₋₄ carbamoyl, et dialkyl C₁₋₄ carbamoyl ;

ou un sel pharmaceutiquement acceptable ou un ester hydrolysable in vivo, de celui-ci.

2. Composé selon la revendication 1, dans lequel R² est un groupe méthyle.
3. Composé selon la revendication 1, dans lequel R¹ est un groupe 1-hydroxyéthyle.
4. Composé selon l'une quelconque des revendications 1 à 3, de formule (IV) :




dans laquelle P¹, R³ et les substituants éventuels de P¹ sont tels que définis dans la revendication 1.

5. Composé selon la revendication 4, dans lequel les substituants éventuels de P¹ sont choisis parmi les groupes halo, cyano, alkyle C₁₋₄, nitro, hydroxy, carboxy, alcoxy C₁₋₄, carbamoyl, amino, trifluorométhyle, et allyloxy.
6. Composé selon la revendication 1, qui est :
 - l'acide (1R, 5S, 6S, 8R, 2'S, 4'S)-2-[2-(8-carboxyquinol-6-ylcarbamoyl)pyrrolidin-4-ylthio]-6-(1-hydroxyéthyl)-1-méthylcarbapénèm-3-carboxylique ; et
 - l'acide (1R, 5S, 6S, 8R, 2'S, 4'S)-2-[2-(6-carboxyquinol-8-ylcarbamoyl)pyrrolidin-4-ylthio]-6-(1-hydroxyéthyl)-1-méthylcarbapénèm-3-carboxylique ;
 - l'acide (1R, 5S, 6S, 8R, 2'S, 4'S)-2-[2-(7-carboxyquinol-5-ylcarbamoyl)pyrrolidin-4-ylthio]-6-(1-hydroxyéthyl)-1-méthylcarbapénèm-3-carboxylique ;
 - l'acide (1R, 5S, 6S, 8R, 2'S, 4'S)-2-[2-(3-carboxyquinol-2-ylcarbamoyl)pyrrolidin-4-ylthio]-6-(1-hydroxyéthyl)-1-méthylcarbapénèm-3-carboxylique ;
 - l'acide (1R, 5S, 6S, 8R, 2'S, 4'S)-2-[2-(2-carboxyquinol-4-ylcarbamoyl)pyrrolidin-4-ylthio]-6-(1-hydroxyéthyl)-1-méthylcarbapénèm-3-carboxylique ;
 - l'acide (1R, 5S, 6S, 8R, 2'S, 4'S)-2-[2-(3-carboxy-6-allyloxyquinol-2-ylcarbamoyl)pyrrolidin-4-ylthio]-6-(1-hydroxyéthyl)-1-méthylcarbapénèm-3-carboxylique ;
 - l'acide (1R, 5S, 6S, 8R, 2'S, 4'S)-2-[2-(2-carboxyquinol-6-ylcarbamoyl)pyrrolidin-4-ylthio]-6-(1-hydroxyéthyl)-1-méthylcarbapénèm-3-carboxylique ;
 - l'acide (1R, 5S, 6S, 8R, 2'S, 4'S)-2-[2-(4-carboxyquinol-8-ylcarbamoyl)pyrrolidin-4-ylthio]-6-(1-hydroxyéthyl)-1-méthylcarbapénèm-3-carboxylique ;
 - l'acide (1R, 5S, 6S, 8R, 2'S, 4'S)-2-[2-(4-carboxyquinol-5-ylcarbamoyl)pyrrolidin-4-ylthio]-6-(1-hydroxyéthyl)-1-méthylcarbapénèm-3-carboxylique ;

- 1-méthylcarbapénèm-3-carboxylique ;
- l'acide (1R, 5S, 6S, 8R, 2'S, 4'S)-2-[2-(2-carboxyquinol-8-ylcarbamoyle)pyrrolidin-4-ylthio]-6-(1-hydroxyéthyl)-1-méthylcarbapénèm-3-carboxylique ;
- l'acide (1R, 5S, 6S, 8R, 2'S, 4'S)-2-[2-(2-carboxyquinol-5-ylcarbamoyle)pyrrolidin-4-ylthio]-6-(1-hydroxyéthyl)-1-méthylcarbapénèm-3-carboxylique ;
- l'acide (1R, 5S, 6S, 8R, 2'S, 4'S)-2-[2-(4-carboxyquinol-2-ylcarbamoyle)pyrrolidin-4-ylthio]-6-(1-hydroxyéthyl)-1-méthylcarbapénèm-3-carboxylique ;
- l'acide (1R, 5S, 6S, 8R, 2'S, 4'S)-2-[2-(7-carboxy-2,3-diméthylquinoxalin-5-ylcarbamoyle)pyrrolidin-4-ylthio]-6-(1-hydroxyéthyl)-1-méthylcarbapénèm-3-carboxylique ;
- l'acide (1R, 5S, 6S, 8R, 2'S, 4'S)-2-[2-(4-carboxyquinazolin-2-ylcarbamoyle)pyrrolidin-4-ylthio]-6-(1-hydroxyéthyl)-1-méthylcarbapénèm-3-carboxylique ;
- l'acide (1R, 5S, 6S, 8R, 2'S, 4'S)-2-[2-(3-carboxyisoquinol-3-ylcarbamoyle)pyrrolidin-4-ylthio]-6-(1-hydroxyéthyl)-1-méthylcarbapénèm-3-carboxylique ;

7. Composition pharmaceutique qui comprend un composé selon l'une quelconque des revendications 1 à 6, et un véhicule pharmaceutiquement acceptable.
8. Procédé de préparation d'un composé selon la revendication 1, qui comprend la déprotection d'un composé de formule (V) :



dans laquelle :


- R^2 est tel que défini dans la revendication 1 ;
- R^{10} est un groupe R^3 (tel que défini dans la revendication 1) ou un groupe amino-protecteur ;
- R^{13} est un groupe R^1 (tel que défini dans la revendication 1), un groupe hydroxyméthyle protégé ou un groupe 1-(hydroxy protégé)éthyle ;
- R^{11} est un atome d'hydrogène ou un groupe carboxy-protecteur ;
- R^{12} est un atome d'hydrogène ou un groupe amino-protecteur ;
- P^1 est tel que défini dans la revendication 1 ;
- R^{18} est un groupe carboxy ou un groupe carboxy protégé ;

et dans laquelle tout substituant éventuel de P^1 est tel que défini dans la revendication 1 et est éventuellement protégé et dans laquelle au moins un groupe protecteur est présent ;
et, ensuite si nécessaire ;


- (i) la formation d'un sel pharmaceutiquement acceptable,
- (ii) l'estérification destinée à former un ester hydrolysable in vivo.

9. Procédé de préparation d'un composé selon la revendication 1, ou d'un composé de formule (V) selon la revendication 8, qui comprend :

(a) la réaction de composés de formules (VI) et (VII) :




(VI)



(VII)

dans lesquelles P¹, R², R¹⁰, R¹¹, R¹², R¹³, et R¹⁸ sont tels que définis dans la revendication 8, les substituants éventuels de P¹ étant tels que définis dans la revendication 8, et L est un groupe partant, ou
(b) la cyclisation d'un composé de formule (VIII) :




(VIII)



dans laquelle P¹, R², R¹⁰, R¹¹, R¹², R¹³, et R¹⁸ sont tels que définis dans la revendication 8, les substituants éventuels de P¹ sont tels que définis dans la revendication 8, et R¹⁴, R¹⁵ et R¹⁶ sont choisis indépendamment parmi les groupes alcoxy C₁₋₆, aryloxy, dialkyl C₁₋₆ amino et diarylamino, ou bien deux quelconques de R¹⁴, R¹⁵ ou R¹⁶ représentent un groupe o-phénylènedioxy, ou bien l'un de R¹⁴, R¹⁵ ou R¹⁶ est un groupe alkyle C₁₋₄, allyle, benzyle ou phényle, et les deux autres sont choisis indépendamment parmi les groupes alkyle C₁₋₄, trifluorométhyle, ou phényle, dans laquelle tout groupe phényle est éventuellement substitué par des groupes alkyle C₁₋₃ ou alcoxy C₁₋₃ ; et dans laquelle tout groupe fonctionnel est éventuellement protégé ; et ensuite si nécessaire :

- (i) le déplacement de tous les groupes protecteurs,
- (ii) la formation d'un sel pharmaceutiquement acceptable,
- (iii) l'estérification destinée à former un ester hydrolysable in vivo.

10. Composé de formule (V) selon la revendication 8, de formule (VII) ou de formule (VIII) selon la revendication 9, ou de formule (IX), de formule (XII) ou de formule (XIV) :



(IX)



dans lesquelles P¹, R², R¹⁰, R¹¹, R¹², R¹³ et R¹⁸ sont tels que définis dans la revendication 8, et R¹⁷ est un groupe protecteur.